Abbreviations

viruses

Viruses

1999-4915

MDPI

10.3390/v4113179

viruses-04-03179

Review

Insight into Alternative Approaches for Control of Avian Influenza in Poultry, with Emphasis on Highly Pathogenic H5N1

Abdelwhab

E. M.

† * Hafez

Hafez M.

Institute of Poultry Diseases, Free Berlin University, Königsweg 63, 14163 Berlin, Germany; Email: hafez@vetmed.fu-berlin.de

†

Present address: Molecular Pathogenesis and Ecology of Influenza Viruses Laboratory, Institute of Molecular Biology, Federal Research Institute for Animal Health, Friedrich Loeffler Institute, Isles of Riems, Suedufer 10, 17493 Greifswald, Germany

* Author to whom correspondence should be addressed; Email: sayed.abdel-whab@fli.bund.de; sayedabdelwhab@yahoo.com; Tel.: +49-30-8386-2679; +49-38-3517-1263; +49-38-3517-1237; Fax: +49-30-838-6267; +49-38-3517-1275.

19 11 2012

11 2012

4 11 3179 3208 23 09 2012 04 11 2012 08 11 2012

2012

This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).

Highly pathogenic avian influenza virus (HPAIV) of subtype H5N1 causes a devastating disease in poultry but when it accidentally infects humans it can cause death. Therefore, decrease the incidence of H5N1 in humans needs to focus on prevention and control of poultry infections. Conventional control strategies in poultry based on surveillance, stamping out, movement restriction and enforcement of biosecurity measures did not prevent the virus spreading, particularly in developing countries. Several challenges limit efficiency of the vaccines to prevent outbreaks of HPAIV H5N1 in endemic countries. Alternative and complementary approaches to reduce the current burden of H5N1 epidemics in poultry should be encouraged. The use of antiviral chemotherapy and natural compounds, avian-cytokines, RNA interference, genetic breeding and/or development of transgenic poultry warrant further evaluation as integrated intervention strategies for control of HPAIV H5N1 in poultry.

influenza H5N1 control

Abbreviations

AIV

avian influenza virus

ChIFN-α

chicken interferon alpha

ChIL

chicken interleukin

ECE

embryonated chicken eggs

hemagglutinin

HPAIV

highly pathogenic avian influenza virus

IFN

interferon

LPAIV

low pathogenic avian influenza virus

myxovirus

neuraminidase

NAIs

neuraminidase inhibitors

rFPV

recombinant fowl pox virus

RIG-I

retinoic acid-inducible gene I

RNA

ribonucleic acid

RNAi

RNA interference

siRNA

short-interfering RNA

SPF

specific pathogen free

TLR

Toll-like receptors

1. Introduction

Influenza A virus, the only orthomyxovirus known to infect birds, are negative-sense, single-stranded, enveloped viruses contain genomes composed of eight separate ribonucleic acid (RNA) segments encode for at least 11 viral proteins. Two surface glycoproteins; hemagglutinin (HA) and neuraminidase (NA) are playing a vital role in attachment and release of the virus, respectively [1]. The 17 HA and 10 NA subtypes of avian influenza viruses (AIV) are classified according to their pathogenicity for poultry into low pathogenic AIV (LPAIV) result in mild or asymptomatic infections and highly pathogenic AIV (HPAIV) causing up to 100% morbidity and mortality [2,3]. To date, some strains of H5 or H7 subtypes fulfilled the defined criteria of high pathogenicity which potentially evolve from low virulent precursors [4]. Constant genetic and antigenic variation of AIV is an intriguing feature for continuous evolution of the virus in nature [5]. Gradual antigenic changes due to acquisition of point mutations known as “antigenic drift” are commonly regarded to be the driving mechanism for influenza virus epidemics from one year to the next. However, possible “antigenic shift or reassortment” of influenza virus occurs by exchange genes from different subtypes is relatively infrequent, however it results in severe pandemics [6].

HPAIV H5N1 is responsible for magnificent economic losses in poultry industry and poses a serious threat to public health [7,8]. Measures to control the virus in domestic poultry are the first step to decrease risks of human infections [9,10]. Enhanced biosecurity measures, surveillance, stamping out and movement restriction as basic principles for control of HPAIV H5N1 epidemics in poultry [11] has not prevented the spread of the virus since 1997 [12,13]. Recently, vaccines have been introduced in some developing countries as a major control tool to reduce the overwhelming socioeconomic impact of HPAI H5N1 outbreaks in poultry [13]. Different types of inactivated vaccines and to lesser extent recombinant live virus vaccines are already in use that decrease shedding of the virus, morbidity, mortality, transmissibility, increase resistance to infection, lower virus replication and limit decrease in egg production [2,14].

Nevertheless, several challenges facing the efficiency of the vaccine to control the HPAIV H5N1 outbreaks have been reported: (1) Vaccine is HA subtype specific and in some regions where multiple subtypes are co-circulating (i.e., H5, H7 and H9), vaccination against multiple HA subtypes is required [15]. (2) Vaccine-induced antibodies hinder routine serological surveillance and differentiation of infected birds from vaccinated ones requires more advanced diagnostic strategies [16]. (3) Vaccination may prevent the clinical disease but can’t prevent the infection of vaccinated birds, thus continuous “silent” circulation of the virus in vaccinated birds poses a potential risk of virus spread among poultry flocks and spillover to humans [17,18,19]. (4) Immune pressure induced by vaccination on the circulating virus increases the evolution rate of the virus and accelerates the viral antigenic drift to evade the host‑immune response [20,21,22,23,24]. (5) After emergence of antigenic variants, the vaccine becomes useless and/or inefficient to protect the birds and periodical update of the vaccine is required [20,25,26,27,28]. (6) Vaccine-induced immunity usually peaks three to four weeks after vaccination and duration of protection following immunization remains to be elucidated [29]. (7) Maternally acquired immunity induced by vaccination of breeder flocks could interfere with vaccination of young birds [30,31,32,33,34]. (8) Other domestic poultry (i.e., ducks, geese, turkeys), zoo and/or exotic birds even within the same species (i.e., Muscovy vs. Pekin ducks) respond differently to vaccination which have not yet been fully investigated compared to chickens [35,36,37,38,39,40,41,42]. (9) Concomitant or prior infection with immunosuppressive pathogens or ingestion of mycotoxins can inhibit the immune response of AIV‑vaccinated birds [43,44,45,46]. (10) And last but not least, factors related to vaccine manufacturing, quality, identity of vaccine strain, improper handling and/or administration can be decisive for efficiency of any AIV vaccine [2,29].

Therefore, presence of new alternative and complementary strategies target different AIV serotypes/subtypes/drift-variants should be encouraged. This review aims to give an insight into possible alternative approaches for control of AIV in poultry particularly against the HPAI H5N1 subtype.

2. Antivirals 2.1. Chemotherapy

The use of chemotherapeutic agents for control of AIV in poultry was concurrently studied just after discovering their anti-microbial effects [47,48]. However, during the last three decades more attention was paid to the commonly used antivirals, M2 blocker and neuraminidase inhibitors (NAIs), in control of human influenza viruses to be used in eradication of AIV in poultry.

2.1.1. M2 Blockers (Adamantanes)

Amantadine hydrochloride and rimantadine are two M2 blockers which interrupt virus life cycle by blocking the influx of hydrogen ions through the M2 ion-channel protein and prevent uncoating of the virus in infected host-cells [49,50,51]. The prophylactic activity of amantadine in poultry was firstly studied by Lang et al. [52] in experimentally infected turkeys with an HPAIV H5N9 isolated in 1966 from Ontario, Canada. Optimum prophylaxis was obtained only when amantadine was administered in an adequate, uninterrupted and sustained amount from at least 2 days pre-infection to 23 days post‑infection. During H5N2 outbreaks in Pennsylvania, USA in early 1980s, one of control proposals was the use of amantadine as a therapeutic and/or prophylactic approach. Under experimental condition, amantadine given in drinking water was efficacious to decrease morbidity, mortality, transmissibility and limit decrease in egg production [53,54]. Nonetheless, all recovered birds were susceptible to reinfection [52,54,55,56] and subclinical infection was reported in most of treated birds [52]. Importantly, amantadine lost its effectiveness as amantadine-resistant mutants emerged within 2–3 days of treatment and killed all in-contact chickens. Amantadine-resistant strains were irreversible, stable and transmissible with pathogenic potential comparable to the wild-type virus. Even more, the resistant mutants replaced the wild-type virus and became dominant [55,56,57]. It is worth pointing out that several subtypes of AIV including the HPAIV H5N1 that currently circulate in both humans and birds around the world are mostly resistant to amantadine [58,59,60,61,62,63,64,65]. Since the late 1990s, positive selection of amantadine-resistant HPAI H5N1 viruses in poultry in China has been proven to be increased due to extensive illegal application of the relatively inexpensive amantadine by some farmers to control HPAIV H5N1 (and LPAIV H9N2) infections in chickens [62,66,67,68,69]. Hence, rapid selection of amantadine-resistant variants threatens the effective use of the drug for control of human influenza epidemics and/or pandemics [70], therefore the extra-label use of amantadine in poultry was banned by all concerned international organizations [71,72]. The second M2 blocker is rimantadine. Because of the unavailability of rimantadine in most countries, its use in poultry is not reported until now in the field. However, Webster et al. [73] mentioned that rimantadine administered in drinking water was efficacious against HPAIV H5N2 infection in experimentally infected chickens. Nonetheless, the emergence of rimantadine-resistant variants was comparable to amantadine.

2.1.2. Neuraminidase Inhibitors (NAIs)

So far, there are two main NAIs, oseltamivir (Tamiflu®) and zanamivir (Relenza®) have been licensed for influenza treatment in human in several countries [74]. When exposed to NAIs, influenza virions aggregate on the host cell surface preventing their release and allow the host immune system to eliminate the virus [75,76]. In the early 2000s, oseltamivir was discovered as a potent and selective inhibitor of the NA enzyme of influenza viruses [50]. It is currently the drug of choice for the treatment of influenza virus infections in human and being stockpiled in many countries in anticipation of a pandemic [77]. Generally, AIV including H5N1 are sensitive to oseltamivir [78] and a small number of H5N1 strains isolated from avian and human origin have been reported to exhibit resistance to oseltamivir [79,80,81,82,83,84]. Oral application of oseltamivir via drinking water reduced the morbidity, mortality, virus excretion and chicken-to-chicken transmission in HPAIV H5N2 experimentally infected chickens [85]. Oseltamivir was non-toxic for chicken embryos and prevented the replication of an HPAIV H7N1 in inoculated eggs [86]. An effective prophylactic administration of oseltamivir in experimentally infected chickens and ducks with LPAI H9N2 and H6N2 viruses was also reported [87]. Although it is very plausible that oseltamivir-resistance mutants emerge after application in poultry, however none of the few studies conducted to evaluate efficacy of oseltamivir in avian species reported emergence of resistant strains. In nature, oseltamivir-resistant H5N1 viruses isolated from domestic and wild birds emerged probably due to spontaneous mutations rather than exposure to oseltamivir [80,88,89,90]. Administration of oseltamivir during an outbreak in commercial flocks is extremely expensive but it could be useful to protect valuable birds [86,87]. On the other hand, zanamivir is currently approved in 19 countries for the treatment and prophylaxis of human influenza [50]. Although, development of zanamivir-resistance in poultry is rare [91], it is not effective in preventing a severe outcome and chicken-to-chicken transmission of an HPAIV H5N2 in experimental chickens [85].

2.2. Natural Antivirals 2.2.1. Herbs

Unlimited herbs products contain polyphenols, flavonoids, alkaloids or lignans, mostly from traditional Chinese medicine, offer promise as adjuncts or alternatives to the current anti-influenza chemotherapy [92,93]. Generally, complementary medicine for treating or preventing influenza or influenza-like illness in human seems to be cultural practice differs from nation to nation [94,95,96]. Innumerable herbs species with potential inhibitory effects on replication of influenza viruses using in‑vitro cell culture methods and embryonated eggs or in-vivo mouse models were frequently described [97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123].

In poultry, antiviral and immunoadjuvant effects of several plants and/or its derivatives have been investigated. In addition to its antiviral activity, these extracts often have anti-bacterial, anti-fungal, anti-inflammatory, anti-oxidant and/or analgesic properties which may provide alternative natural broad-spectrum therapy for control of AIV in poultry farms [124,125,126,127]. Sood et al. [127] found that Eugenia jambolana extracts had 100% virucidal activity against HPAIV H5N1 in tissue culture and in‑ovo inoculated chicken embryonated eggs (ECE). Menthol, eucalyptol and ormosinine probably have inhibitory effect on H5 viruses due to strong interactions ability with the viral HA protein [128]. NAS preparation, a Chinese herbal medicine, prevented H9N2 virus-induced clinical signs in treated chickens; however transmission of the virus to untreated chickens was not interrupted [129]. Likewise, eucalyptus and peppermint essential oils preparations protected broilers against H9N2 virus infections [130,131]. Moreover, application of lyophilized green tea by-product extracts namely catechins in feed or drinking water reduced H9N2 virus replication and excretion in experimentally infected chickens in a dose-dependent manner [132]. In addition, green tea extract was comparable to amantadine in protection of chicken embryos against H7N3 subtype [120]. Catechins alter the infectivity of influenza viruses probably not only by direct interaction with viral HA but also by inhibition of viral RNA synthesis in cell culture [133]. Furthermore, Liu et al. [134] found that statin/caffeine combination was as effective as oseltamivir in reduction HPAIV H5N1-induced lung damage and viral replication in mice.

The immunoadjuvant effect of some herbal extracts as feed additives on the humoral immune response induced by inactivated AIV vaccination in poultry has been studied. Oral administration of ginseng stem-and-leaf saponins in drinking water or Hypericum perforatum L. as a dietary supplement significantly enhanced serum antibody response to inactivated H5N1 or H9N2 vaccines in chickens [135,136,137]. The Cochinchina momordica seed extract, Chinese medicine plant, when combined with an inactivated H5N1 vaccine as adjuvant increased significantly the immune response and daily weight gain of two weeks old chickens [138]. On the contrary, herbal extracts of Radix astragali, Radix codonopis, Herba epimedii and Radix glycyrrizae in drinking water did not improve chicken immune response to H5-AIV vaccination [139], likewise diet supplementation with fresh garlic powder had no effect on the humoral immune response of chickens vaccinated with an inactivated H9N2 vaccine [140].

Yet, some derivatives (i.e., ginseng saponins) require four to six years to harvest and is very expensive on the market [135]. Methods of the extraction and preparation of the crude extracts and its purity greatly influence the inhibition activity of some herbs against AIV [132,133]. Moreover, batch‑to-batch variations due to variable growth conditions at the plantations have been considered a limiting factor for treatment of influenza [124]. Evident that mutation in the H5 gene probably affects inhibitor binding of some herbs was reported [128]. In addition, in-vitro experiments and animal models to confirm the direct antiviral activities against influenza virus are limited [141]. Moreover, comprehensive investigations of herb-drug interactions, potential toxicity, heterogeneity of herbs species, plant parts (i.e., aerial vs. root) and biochemical data identifying the active components are inadequately described [142].

2.2.2. Probiotics

A number of studies have reported the efficacy of probiotic lactic acid bacteria such as Streptococcus thermophiles, several Lactobacillus and Bifidobacterium species to enhance the immune response and to protect mice against different influenza strains/serotypes [143,144,145,146,147,148,149,150,151,152]. Although probiotics are widely used in poultry to improve innate and adaptive immunity [153,154,155], there is a paucity of information on its ability to ameliorate AIV infections. Lactobacillus plantarum KFCC11389P was as effective as oseltamivir to neutralize the H9N2 virus in ECE and slightly reduced amount of tracheal virus excretion in oral-fed experimentally infected chickens [156]. Out of 220 screened bacterial strains, Seo et al. [157] found that Leuconostoc mesenteroides YML003 had highly anti-H9N2 activity in cell culture and ECE. Decrease cloacal excretion of the virus and a significant increase in the cytokine IFN-gamma in experimentally infected chickens were observed. Ghafoor and co-workers [158] showed that multi-strains commercial probiotic protexin® (various Lactobacillus sp., Enterococcus faecium, Bifidobacterium bifidum, Candida pintolepesii and Aspergillus oryzae) improved immune response of broiler chickens to H9N2 vaccination and prevented the mortality and morbidity. On the other hand, dual use of Lactobacillus spp. or Lactococcus lactis as a vector for vaccine production and immunomodulation bacteria has been successfully constructed and protected mice against HPAIV H5N1 [159,160], such experiments should be evaluated in poultry.

3. Molecular Approaches for Control of AIV 3.1. Avian-Cytokines

Chicken cytokines such as chicken interferon-alpha (ChIFN-α), chicken interleukins (ChIL) and Toll-like receptors (TLR) are essential components of chicken’s innate immune system which play a vital role against virus infections [15,161,162,163]. An innovative application of ChIFN-α to antagonize AIV infection in poultry through direct oral feeding or drinking water has received more attention than other components [164,165,166,167,168]. Sekellick et al. [169] showed that up to 60% of investigated AIV population belonged to the HPAI H5N9 subtype were highly sensitive to the inhibitory effects of ChIFN-α. Interestingly, both IFN-sensitive and -resistant clones were obtained after passage of the resistant clones in the presence of IFN which indicated that resistance to ChIFN-α was transient and did not result from stable genetic changes. Xia et al. [170] cloned the ChIFN-α gene from three different chicken lines and studied their efficacy against H9N2 viruses in-ovo and in-vivo. Up to 70% of in-ovo treated chicken embryos were protected against H9N2 virus infection in dose dependent manner. Moreover, chickens received ChIFN-α by oculonasal inoculation at one day of age were protected from death upon H9N2 virus infection given 24 hours later. Findings of Meng and co‑workers [166] showed that oral administration of exogenous ChIFN-α was effective to prevent and treat chickens experimentally infected with an H9N2 virus. It potentially reduced the viral load in trachea and resulted in rapid recovery of the body weight gain. In another study, White Leghorn (WL) chickens received ChIFN-α in drinking water for 14 successive days augmented detectable humoral anti-influenza antibodies after exposure to a low dose of an LPAIV H7N2 infection [164]. Thus, it has been suggested that regular water administration of ChIFN-α can create “super-sentinel” chickens to detect early infections with few amount of LPAIV [164].

Furthermore, oral administration of live attenuated Salmonella enterica serovar Typhimurium expressing ChIFN-α alone or in combination with ChIL-18 significantly reduced clinical signs induced by H9N2 virus and decreased the amount of virus load in cloacal swabs and internal organs [171,172]. Likewise, chicken immunized with a recombinant fowl pox virus (rFPV) vaccine expressing both the HA gene of H9N2 virus and ChIL-18 survived challenge with an H9N2 virus and did not excrete any virus in swab samples and/or internal organs in comparison to non-vaccinated birds [173]. Also, rFPV expressing the H5, H7 and ChIL-18 genes produced significantly higher humoral and cellular mediated immune response and protected specific pathogen free chickens (SPF) and WL chickens against challenge with an HPAIV H5N1. Vaccinated birds had no virus shedding and showed significant increase in body weight gain [174]. So far, efficiency of avian-cytokines to limit AIV infection has not been adequately studied in other avian species. The duck IL-18 and IL-2 genes had been identified and shown to have 85% and 55% nucleotide identity to the chicken equivalents, respectively. Intramuscular inoculations of the duck IL-18 or IL-2 enhanced the humoral immune response of ducks vaccinated with H5N1 or H9N2 inactivated vaccines, respectively [175,176]. Likewise, the recombinant goose IL-2 strengthens goose humoral immune responses after vaccination using H9N2 inactivated vaccine [177].

The TLR-3, TLR-7 and TLR9 are other promising chicken cytokines derivatives that showed broad-spectrum anti-influenza virus activity in-vitro and in-ovo [178,179,180,181]. Nevertheless, the cost of mass production of chicken cytokines is still too high to be applied in large-scale in poultry industry [165]. Moreover, protein stability, host-specificity and labor associated with mass administration of chicken cytokines under field conditions require significant improvement [172].

3.2. RNA Interference (RNAi)

RNAi is a natural phenomenon used by many organisms as a defense mechanism against foreign microbial invasion, including viruses, that able to wreak potential genetic havoc of the susceptible host [182]. Short-interfering RNA (siRNA) is approximately 21–25 nucleotides specific for highly conserved regions of AIV genomes. It effectively mediates the catalytic degradation of complementary viral mRNAs and results in inhibition of a broad spectrum of influenza viruses replication in cell lines, chicken embryos and mice just before or after initiation of an infection [183,184,185,186,187]. Tompkins and colleagues [188] found that siRNA specific for the NP or PA genes induced full protection of mice against lethal challenge with the HPAI H5N1 and H7N7 subtypes and markedly decreased virus titers in lungs. Likewise, prophylactic use of PA-specific siRNA molecule significantly reduced lung H5N1 virus titers and lethality in infected mice [189]. Moreover, siRNA targeting M2 or NP genes inhibited replication of H5N1 and H9N2 viruses in canine cell line and partially protected mice against HPAV H5N1 [190].

In poultry, Li and others [191] showed that the siRNA targeting NP and/or PA genes inhibited protein expression, RNA transcription and multiplication of HPAIV H5N1 in chicken embryo fibroblasts and ECE as well as prevented apoptosis of infected cells. Likewise, chicken cell line transfected with RNAi molecules specific for the NP or PA of AIV showed decrease the levels of NP mRNA and infective titre of an H10N8 quail virus [192]. Also, NP-specific siRNA reduced H5N1 virus replication in cell culture and ECE [186]. Moreover, siRNA molecules targeting the NP, PA and PB1 genes interfered with replication of H1N1 virus in ECE [184].

In contrast to AIV vaccines, siRNA might not require an intact immune system [193] which is very important particularly in developing countries where a number of immunosuppressive agents are endemic in poultry. In addition, siRNA molecules targeting the highly conserved regions in influenza genome potentially remain effective regardless AIV subtype/serotype variations and despite antigenic drift and shift of AIV [193,194]. Moreover, it has also the potential to reduce the emergence of viable resistant variants [10], in this regard combinations of siRNA molecules “cocktail” targeting several genes/regions may be used simultaneously [195,196]. Furthermore, there is no risk of recombination between siRNA nucleotides and circulating influenza viruses, hence siRNA is complementary to the influenza virus genome [10]. Moreover, the siRNA dose required for inhibition of AIV is very low (sub-nanomoles) [195]. Nevertheless, arise of mutants with the ability to evade the inhibition effect of siRNA are not fully excluded [193]. Unfortunately, there is no stretch of conserved nucleotides in the NA and HA genes sufficient to generate specific siRNA due to extensive variations in these genes among AIV from different species [195]. The siRNA molecules are quickly degraded in-vivo affording a transient short-term protection and multiple-dose is required [192]. None of the siRNAs must share any sequence identity with the host genome to avoid non-specific RNAi-induced gene silencing of the host cells [195,197,198,199]. Delivery vehicle of siRNA to the site of infection is a major constraint [200,201] remained to be investigated on flock-level in poultry. There is accumulating evidence that siRNA is efficient to inhibit influenza virus replication in-vitro, however in-vivo studies still missing. Research studies focus on mass application of siRNA in poultry as a spray or via drinking water are highly recommended [202].

3.3. Host Genetic Selection

The host genetics play a pivotal role in susceptibility to influenza including the HPAIV H5N1 which is frequently studied in mice models as reviewed by Horby et al. [203]. Indeed, the impact of host genetic selection on resistance to AIV infections in poultry has not yet been fully determined. The on-going H5N1 virus epidemics have raised concerns in respect to influenza-resistant chickens either by selective breeding or genetic modification.

3.3.1. Natural Resistance

It has been supposed that fast-growing domestic birds have reduced immune competence against several viral diseases and resistant breeds are mostly poor producers [204]. Natural resistance or less susceptibility of some species/breeds of birds to AIV is not uncommon. In an experiment, five chicken lines were infected with an HPAIV H7N1. Three lines showed high susceptibility to the virus while two lines showed some resistance and survived the infection [205]. Swayne et al. [206] observed that an LPAIV H4N8 produced more severe lesions in commercial and SPF WL chickens than in 5 week‑old commercial broiler chickens suggesting that SPF WL chickens are more susceptible than broilers to this strain. Thomas et al. [207] suggested that WL chickens may be more susceptible to an H3N2 virus of swine origin than White Plymouth Rock broiler-type chickens. On the contrary, severe lesions in commercial broiler chickens compared to SPF was observed after experimental infection with a Jordanian H9N2 isolate [208]. Some wild duck species, particularly mallards, are more resistance to HPAIV H5N1 than others [209]. Conversely, dabbling ducks and white fronted goose were more frequently infected with AIV than other wild ducks and geese, respectively [210]. Wood ducks were the only species to exhibit illness or death between different species of experimentally infected wild ducks in a study conducted by Brown and others [211].

3.3.1.1. Myxovirus (Mx) Resistance Gene

Myxovirus resistance gene is an interferon-stimulated gene encodes Mx1 protein that able to interfere with AIV replication by inhibiting viral polymerases in the nucleus and by binding viral components in the cytoplasm. The role of the Mx gene in resistance against influenza viruses including the HPAIV H5N1 in mammals is well defined [212,213,214,215,216,217,218]. However, the contribution of avian Mx proteins as antiviral elements in AIV infection in birds is contradictory and worth further exploration. Although intra- and inter-breed/-species Mx variations have been frequently reported [205,219,220,221,222,223,224,225,226], however commercial chicken lines have lower frequencies of the resistant allele compared to the indigenous chicken breeds [219,220,227] probably due to intensive modern breeding techniques [228]. Duck Mx was the first avian Mx protein to be characterized but no antiviral activity against an HPAIV H7N7 when transfected in chicken and mouse cells was obtained [229]. On the contrary, chickens have a single Mx1 gene [230] with multiple alleles [220] encoding a deduced protein with 705 amino acids in length. Notably, results of anti-influenza activity of the Mx1 protein in chickens are contradictory likely due to using variable experimental setups and different AIV strains. Also, a similar disparity has been noted between in-vitro and in-vivo experiments [205,231].

Phenotypic variation in the antiviral activity of Mx gene has been linked to a single amino acid substitution of asparagine (Asn) at position 631 in resistant breeds or serine (Ser) in sensitive ones [219]. The 631Asn identified mostly in Japanese native chicken breeds screened by Ko et al. [219] was associated with enhanced antiviral activity to H5N1 virus in transfected mouse fibroblast 3T3 cells. Conversely, results obtained by Benfield et al. [232,233] and Schusser et al. [234] indicated that neither the 631Asn nor the 631Ser genotypes of chicken Mx1 was able to confer protection against several LPAIV and HPAIV including H5N1 subtype in chicken embryo fibroblasts or ECE. Similarly, Mx1 631Asn had no effect on viral replication after in-vitro infection of chicken embryo kidney cells with an LPAIV H5N9 [231]. Moreover, transfected chicken cells expressing chicken Mx protein did not induce resistance to HPAIV H7N7 [235]. In-vivo, following intranasal infection with an HPAIV H5N2, chickens carry Asn631 allele showed delayed mortality, milder morbidity and lesser virus excretion than 631Ser homozygotes [231]. Conversely, no correlation was observed between Mx-631 genotypes and susceptibility of chickens to an HPAIV H7N1 as indicated by clinical status and time course of infection [205]. Although, one out of six chicken lines infected with an HPAIV H7N1 had lower mortality, the Mx gene was not involved in this variations among tested chicken lines [236]. Additionally, chickens carry the homozygous Mx resistant allele genotype augmented the lowest HI titer after vaccination with an inactivated H5N2 vaccine compared with chickens that carry the sensitive allele [237].

Taken together, resistance or susceptibility to a disease is usually multifactorial in nature and greatly influenced by both the host and the virus, therefore the role of Mx1 gene merits more in-depth investigation [224,234]. In-vivo comparative studies using several native breeds from different countries are required to elucidate the role of Mx1 gene in AIV resistance [231].

3.3.1.2. Other Candidate Genes

Apart from the Mx1 gene, resistance or less susceptibility of ducks to AIV infections compared with chickens has been linked to an influenza virus sensor known as retinoic acid-inducible gene I “RIG-I” (a cytoplasmic RNA sensor contribute to AIV detection and IFN production) which is absent in chickens [238,239,240]. This RIG-I gene as a natural AIV resistance gene in ducks could be a promising candidate for creation of transgenic chickens [238]. Moreover, different genes and cytokines have been expressed after infection of chicken and duck cells with several AIV subtypes including HPAIV H5N1 [241,242,243,244]. Additional genetic candidates that contribute to inhibition of AIV replication could be useful in creation of genetically modified chickens such as cyclophilin A [245], ISG15 [246], viperin [247], heat shock cognate protein 70 (Hsc70) [248] or Ebp1 and/or ErbB3-binding protein [249].

3.3.2. Transgenic Chickens

Current advance in molecular biology and genetic manipulation can facilitate the development of influenza-resistant poultry. Increase resistance of cell lines to influenza virus infection using RNA interfering (RNAi) molecules expressed by a lentiviral vector is more efficient transgenic tool than direct DNA injection or oncoretroviral vectors infection [10,250,251]. Recently, creation of AIV built‑in resistant chickens by genetic modification has been experimentally proven by Lyall and colleagues [252]. Chickens equipped with a short-hairpin RNA targets the AIV polymerase binding sites have been created and infected with HPAIV H5N1. Although all infected transgenic birds succumbed to the infection however the virus did not spread to the in-contact transgenic and non‑transgenic cagemates [252]. Applicability in food production, safety regulations and consumer’s preferences are important challenges face development of genetically modified chickens [252,253]. Moreover, AIV is a “master of mutability” and global production of the resistant chickens must be equipped with many decoys target different genes to avoid rapid generation of AIV resistance. In addition, replacement of the commercial flocks with the newly flu-resistant birds is expected to occur within short period due to globalization of the poultry industry however replacement of backyard birds seems to be more complicated [253].

4. Summary and Perspectives

Epidemics of avian influenza in poultry are a real challenge for the scientific community [12]. Recently, several approaches to control the disease were developed and have yielded promising results. Although beneficial, these approaches face different limitations and restrictions (Table 1). The use of antiviral drugs in poultry could be an ancillary tool to control AIV infections in valuable birds but not in commercial sectors. Fears of kicking out our leading antiviral drugs in control of AIV are increased by adoption of amantadine (and probably oseltamivir) in poultry and transmission of resistant variants to human. On the other hand, limited supply and high costs of oseltamivir preclude its widespread use for poultry. Compliance with other medications, adverse effects and drug residues in eggs, meat and surrounding environment should be investigated. On the other hand, effectiveness of herbal and cytokines-based medications to protect against HPAIV H5N1 should be seriously considered and further investigation in-vivo is inevitable.

Molecular approaches including RNAi and transgenic chickens for control of AIV are encouraging. The use of short interfering RNA prevents the replication of AIV seems to be a promising approach; however specificity to the viral genome without interference with the host genome and non‑specifically inhibition of cellular gene activity is critical. Delivery to the host, production costs, mass production and application, storage and handling of the final products are important aspects that remain unresolved. Possibility for arise of mutants with the ability to evade the siRNA activity should also be considered. Genetic resistance to AIV determined by only one point mutation in the Mx gene or complex and multigenic host components as recently determined in mice [254] should be firstly confirmed and secondly elucidation of its relation to the productivity of birds and other diseases must be considered.

Although a proof-of-principle to produce transgenic chickens has been recently reported, technical, logistic and social constraints are facing development of chicken resistant to AIV. Stable transmission and expression of the transgene from generation to generation require extensive studies. Regulatory approval, mass production, costs and marketing of commercial AIV resistant pedigree lines, consumer preferences and food safety issues need to be carefully and fully addressed. Overall, mutation of the virus in the face of any control approach remains the real challenge. Influenza epidemics and pandemics will likely continue to cause havoc in poultry and human populations, therefore innovative alternative or complementary intervention strategies need to be developed. The ultimate goal of all control (including alternate) strategies must be the eradication of avian influenza. In this context, alternate approaches might be an aid but should not jeopardize surveillance and current control measures.

viruses-04-03179-t001_Table 1

Table 1

Advantages and limitations of different alternative approaches for control of avian influenza viruses in poultry.

Approach		Advantages	Limitations
Antivirals	Chemotherapy
	M2 Blockers (Amantadine and Rimantadine) and Neuraminidase inhibitors (Oseltamivir and Zanamivir)	Rapid protection Mass administration (feed, water) Cost-effective for individual birds (amantadine HCL) Suitable for all types of birds against all types of AIV	Hazards of kicking out cornerstone antivirals in case of pandemic Emergence of resistant mutants Require long application period to be effective Expensive in flock level (Oseltamivir) Residues in meat and eggs was not fully addressed Compliance with other medical agents need to be considered
	Natural Antivirals
	Herbs	Direct antiviral activity Immunoadjuvant effect Additional effects as antioxidants, anti-inflammatory, etc. No adverse effects on body weight, egg production	Extraction is very expensive Affection with antigenic changes, herb-drug interactions, cytotoxicity and biochemical traits were not fully investigated Extraction methods, preparation, purity of the crude extracts greatly influence the efficacy. Batch-to-batch variations are high due to variable plantations conditions. Animal models of infection are limited
	Probiotics	Direct and indirect antiviral activity Immunoadjuvant effect Dual use as a vaccine-vector and immunomodulator	Efficacy against AIV particularly HPAIV is still questionable
Molecular approaches	Avian Cytokines	Not affected by antigenic changes Broad spectrum antiviral activities	Instability High production costs No mass production Field application limitations
	RNA interference	Inhibition of any influenza subtype/serotype/variant High specificity to particular strain/subtype/variant Do not require intact immune system Use as a prophylactic and/or therapeutic	Specificity to the viral genome without interference with the host genome and non-specifically inhibition of cellular gene activity is critical. Delivery to the host, costs, mass production, storage and handling of the final products consider questionable aspects. Possibility for arise of mutants with the ability to evade the siRNA activity should not be fully guaranteed Quickly degraded in-vivo Induce a transient & short-term protection and multiple-dose is required In-vivo research studies still missing
	Naturally resistant birds (Myxovirus Mx resistant gene and other candidate genes)	Few breeds of chickens and ducks can survive challenge with HPAIV in nature	Results on the contribution of the Mx gene to AIV resistant are contradictory Resistant breeds are mostly low producer native breeds. Interrelation of disease-resistance and production should be weighed Studies have been conducted only on a limited number of native breeds in some countries
	Transgenic birds	Although all infected transgenic birds succumbed to the infection however the virus did not spread to the in-contact transgenic and non-transgenic cagemates	Replacement of backyard flocks Consumer preferences Food safety Regulatory approval Costs of production Mutations of AIV

Conflict of Interest

The authors declare no conflict of interest.

References and Notes 1.

Palese

Shaw

M.L.

Orthomyxoviridae: The viruses and their replication

Fields Virology 5th

Knipe

D.M.

Howley

P.M.

Lippincott Williams & Wilkins

Philadelphia, PA, USA

2007 1647 1689 2.

Swayne

D.E.

Avian influenza vaccines and therapies for poultry

Comp. Immunol. Microbiol. Infect. Dis. 2009 32 351 363

10.1016/j.cimid.2008.01.006

Tong

Rivailler

Conrardy

Castillo

D.A.

Chen

L.M.

Recuenco

Ellison

J.A.

Davis

C.T.

York

I.A.

A distinct lineage of influenza A virus from bats

Proc. Natl. Acad. Sci. U. S. A. 2012 109 4269 4274

22371588

Lupiani

Reddy

S.M.

The history of avian influenza

Comp. Immunol. Microbiol. Infect. Dis. 2009 32 311 323

10.1016/j.cimid.2008.01.004

18533261

Brown

E.G.

Influenza virus genetics

Biomed. Pharmacother. 2000 54 196 209

10.1016/S0753-3322(00)89026-5

Ferguson

N.M.

Galvani

A.P.

Bush

R.M.

Ecological and immunological determinants of influenza evolution

Nature 2003 422 428 433

10.1038/nature01509

12660783

Webster

R.G.

Bean

W.J.

Gorman

O.T.

Chambers

T.M.

Kawaoka

Evolution and ecology of influenza A viruses

Microbiol. Rev. 1992 56 152 179

1579108

Peiris

J.S.

de Jong

M.D.

Guan

Avian influenza virus (H5N1): A threat to human health

Clin. Microbiol. Rev. 2007 20 243 267

10.1128/CMR.00037-06

Mumford

Bishop

Hendrickx

Embarek

P.B.

Perdue

Avian influenza H5N1: Risks at the human-animal interface

Food Nutr. Bull. 2007 28 S357 S363

17658082

10.

Chen

S.C.

Stern

Scott

B.B.

Lois

Genetic strategy to prevent influenza virus infections in animals

J. Infect. Dis. 2008 197 S25 S28

10.1086/524987

18269324

11.

Yee

K.S.

Carpenter

T.E.

Cardona

C.J.

Epidemiology of H5N1 avian influenza

Comp. Immunol. Microbiol. Infect. Dis. 2009 32 325 340

10.1016/j.cimid.2008.01.005

12.

Capua

Alexander

D.J.

The challenge of avian influenza to the veterinary community

Avian Pathol. 2006 35 189 205

10.1080/03079450600717174

13.

Swayne

D.E.

Pavade

Hamilton

Vallat

Miyagishima

Assessment of national strategies for control of high-pathogenicity avian influenza and low-pathogenicity notifiable avian influenza in poultry, with emphasis on vaccines and vaccination

Rev. Sci. Tech. 2011 30 839 870

22435196

14.

van den Berg

Lambrecht

Marche

Steensels

Van Borm

Bublot

Influenza vaccines and vaccination strategies in birds

Comp. Immunol. Microbiol. Infect. Dis. 2008 31 121 165

10.1016/j.cimid.2007.07.004

15.

Suarez

D.L.

Schultz-Cherry

Immunology of avian influenza virus: A review

Dev. Comp. Immunol. 2000 24 269 283

10.1016/S0145-305X(99)00078-6

10717293

16.

Suarez

D.L.

Overview of avian influenza DIVA test strategies

Biologicals 2005 33 221 226

10.1016/j.biologicals.2005.08.003

17.

Savill

N.J.

St Rose

S.G.

Keeling

M.J.

Woolhouse

M.E.

Silent spread of H5N1 in vaccinated poultry

Nature 2006 442 757

10.1038/442757a

16915278

18.

Capua

Alexander

D.J.

Ecology, epidemiology and human health implications of avian influenza viruses: Why do we need to share genetic data?

Zoonoses Public Hlth. 2008 55 2 15

10.1111/j.1863-2378.2007.01081.x

19.

Hafez

M.H.

Arafa

Abdelwhab

E.M.

Selim

Khoulosy

S.G.

Hassan

M.K.

Aly

M.M.

Avian influenza H5N1 virus infections in vaccinated commercial and backyard poultry in Egypt

Poultry Sci. 2010 89 1609 1613

10.3382/ps.2010-00708

20.

Lee

C.W.

Senne

D.A.

Suarez

D.L.

Effect of vaccine use in the evolution of Mexican lineage H5N2 avian influenza virus

J. Virol. 2004 78 8372 8381

10.1128/JVI.78.15.8372-8381.2004

21.

Cattoli

Fusaro

Monne

Coven

Joannis

El-Hamid

H.S.

Hussein

A.A.

Cornelius

Amarin

N.M.

Mancin

Evidence for differing evolutionary dynamics of A/H5N1 viruses among countries applying or not applying avian influenza vaccination in poultry

Vaccine 2011 29 9368 9375

10.1016/j.vaccine.2011.09.127

22.

Cattoli

Milani

Temperton

Zecchin

Buratin

Molesti

Aly

M.M.

Arafa

Capua

Antigenic drift in H5N1 avian influenza virus in poultry is driven by mutations in major antigenic sites of the hemagglutinin molecule analogous to those for human influenza virus

J. Virol. 2011 85 8718 8724

10.1128/JVI.02403-10

21734057

23.

Boni

M.F.

Vaccination and antigenic drift in influenza

Vaccine 2008 26 C8 C14

10.1016/j.vaccine.2008.04.011

18773534

24.

Escorcia

Vazquez

Mendez

S.T.

Rodriguez-Ropon

Lucio

Nava

G.M.

Avian influenza: Genetic evolution under vaccination pressure

Virol. J. 2008 5 15

10.1186/1743-422X-5-15

25.

Abdelwhab

E.M.

Grund

Aly

M.M.

Beer

Harder

T.C.

Hafez

H.M.

Multiple dose vaccination with heterologous H5N2 vaccine: Immune response and protection against variant clade 2.2.1 highly pathogenic avian influenza H5N1 in broiler breeder chickens

Vaccine 2011 29 6219 6225

10.1016/j.vaccine.2011.06.090

21745517

26.

Grund

Abdelwhab el

S.M.

Arafa

A.S.

Ziller

Hassan

M.K.

Aly

M.M.

Hafez

H.M.

Harder

T.C.

Beer

Highly pathogenic avian influenza virus H5N1 from Egypt escapes vaccine-induced immunity but confers clinical protection against a heterologous clade 2.2.1 Egyptian isolate

Vaccine 2011 29 5567 5573

10.1016/j.vaccine.2011.01.006

21244859

27.

Kilany

W.H.

Abdelwhab

E.M.

Arafa

A.S.

Selim

Safwat

Nawar

A.A.

Erfan

A.M.

Hassan

M.K.

Aly

M.M.

Hafez

H.M.

Protective efficacy of H5 inactivated vaccines in meat turkey poults after challenge with Egyptian variant highly pathogenic avian influenza H5N1 virus

Vet. Microbiol. 2011 150 28 34

10.1016/j.vetmic.2010.12.016

28.

Rauw

Palya

Van Borm

Welby

Tatar-Kis

Gardin

Dorsey

K.M.

Aly

M.M.

Hassan

M.K.

Soliman

M.A.

Further evidence of antigenic drift and protective efficacy afforded by a recombinant HVT-H5 vaccine against challenge with two antigenically divergent Egyptian clade 2.2.1 HPAI H5N1 strains

Vaccine 2011 29 2590 2600

10.1016/j.vaccine.2011.01.048

29.

Swayne

D.E.

Kapczynski

Strategies and challenges for eliciting immunity against avian influenza virus in birds

Immunol. Rev. 2008 225 314 331

10.1111/j.1600-065X.2008.00668.x

30.

Maas

Rosema

van Zoelen

Venema

Maternal immunity against avian influenza H5N1 in chickens: Limited protection and interference with vaccine efficacy

Avian Pathol. 2011 40 87 92

10.1080/03079457.2010.541226

21331952

31.

Sarfati-Mizrahi

Lozano-Dubernard

Soto-Priante

Castro-Peralta

Flores-Castro

Loza-Rubio

Gay-Gutierrez

Protective dose of a recombinant Newcastle disease LaSota-avian influenza virus H5 vaccine against H5N2 highly pathogenic avian influenza virus and velogenic viscerotropic Newcastle disease virus in broilers with high maternal antibody levels

Avian Dis. 2010 54 239 241

10.1637/8735-032509-Reg.1

32.

Abdelwhab

E.M.

Grund

Aly

M.M.

Beer

Harder

T.C.

Hafez

H.M.

Influence of maternal immunity on vaccine efficacy and susceptibility of one day old chicks against Egyptian highly pathogenic avian influenza H5N1

Vet. Microbiol. 2012 155 13 20

10.1016/j.vetmic.2011.08.004

21920677

33.

De Vriese

Steensels

Palya

Gardin

Dorsey

K.M.

Lambrecht

Van Borm

van den Berg

Passive protection afforded by maternally-derived antibodies in chickens and the antibodies' interference with the protection elicited by avian influenza-inactivated vaccines in progeny

Avian Dis. 2010 54 246 252

10.1637/8908-043009-Reg.1

34.

Kim

J.K.

Kayali

Walker

Forrest

H.L.

Ellebedy

A.H.

Griffin

Y.S.

Rubrum

Bahgat

M.M.

Kutkat

M.A.

Ali

M.A.

Puzzling inefficiency of H5N1 influenza vaccines in Egyptian poultry

Proc. Natl. Acad. Sci. U. S. A. 2010 107 11044 11049

10.1073/pnas.1006419107

20534457

35.

Martelli

Hock

O.S.

Luz

Furley

Chiek

E.J.

Wee

L.C.

Keun

N.M.

Field study on the use of inactivated H5N2 vaccine in avian species

Vet. Rec. 2005 157 299 300

16157578

36.

Philippa

J.D.

Munster

V.J.

Bolhuis

Bestebroer

T.M.

Schaftenaar

Beyer

W.E.

Fouchier

R.A.

Kuiken

Osterhaus

A.D.

Highly pathogenic avian influenza (H7N7): Vaccination of zoo birds and transmission to non-poultry species

Vaccine 2005 23 5743 5750

10.1016/j.vaccine.2005.09.013

16298028

37.

Cagle

T.L.

Nguyen

Wasilenko

Adams

S.C.

Cardona

C.J.

Spackman

Suarez

D.L.

Pantin-Jackwood

M.J.

Pekin and Muscovy ducks respond differently to vaccination with a H5N1 highly pathogenic avian influenza (HPAI) commercial inactivated vaccine

Vaccine 2011 29 6549 6557

10.1016/j.vaccine.2011.07.004

21771626

38.

Lecu

De Langhe

Petit

Bernard

Swam

Serologic response and safety to vaccination against avian influenza using inactivated H5N2 vaccine in zoo birds

J. Zoo Wildl. Med. 2009 40 731 743

10.1638/2008-0044.1

39.

Kapczynski

D.R.

Swayne

D.E.

Influenza vaccines for avian species

Curr. Top. Microbiol. Immunol. 2009 333 133 152

19768403

40.

Koch

Steensels

van den Berg

Vaccination of birds other than chickens and turkeys against avian influenza

Rev. Sci. Tech. 2009 28 307 318

19618634

41.

Tian

Zhang

Liu

Zhou

Shi

Chen

Protective efficacy in chickens, geese and ducks of an H5N1-inactivated vaccine developed by reverse genetics

Virology 2005 341 153 162

10.1016/j.virol.2005.07.011

16084554

42.

Bertelsen

M.F.

Klausen

Holm

Grondahl

Jorgensen

P.H.

Serological response to vaccination against avian influenza in zoo-birds using an inactivated H5N9 vaccine

Vaccine 2007 25 4345 4349

10.1016/j.vaccine.2007.03.043

43.

Robinson

J.H.

Easterday

B.C.

Avian influenza virus infection of the immunosuppressed turkey

Am. J. Vet. Res. 1979 40 1219 1222

230771

44.

Hao

Y.X.

Yang

J.M.

Liu

McAllister

T.A.

Reduced serologic response to avian influenza vaccine in specific-pathogen-free chicks inoculated with Cryptosporidium baileyi

Avian Dis. 2008 52 690 693

10.1637/8370-052608-Reg.1

19166065

45.

Sun

Cui

Wang

Protective efficacy of vaccination against highly pathogenic avian influenza is dramatically suppressed by early infection of chickens with reticuloendotheliosis virus

Avian Pathol. 2009 38 31 34

10.1080/03079450802607504

46.

Hegazy

A.M.

Abdallah

F.M.

Abd-El Samie

L.K.

Nazim

A.A.

The relation between some immunosuppressive agents and widespread nature of highly pathogenic avian influenza (HPAI) post vaccination

Am. J. Sci. 2011 7 66 72 47.

Tolba

M.K.

Eskarous

J.K.

Response of some strains of Newcastle disease and fowl-plague viruses to two quinones

Arch. Mikrobiol. 1959 34 325 332

10.1007/BF00447094

13838680

48.

Moses

H.E.

Brandly

C.A.

Jones

E.E.

Jungherr

E.L.

The Isolation and Identification of Fowl Plague Virus

Am. J. Vet. Res. 1948 9 314 328 49.

Sugrue

R.J.

Tan

B.H.

Yeo

D.S.

Sutejo

Antiviral drugs for the control of pandemic influenza virus

Ann. Acad. Med. Singapore 2008 37 518 524

18618065

50.

Kamps

B.S.

Hoffman

Drug profiles

Influenza Report 2006 Kamps

B.S.

Hoffman

Preiser

Flying Publisher

Paris, France

2006 188 221 51.

Kato

Eggers

H.J.

Inhibition of uncoating of fowl plague virus by l-adamantanamine hydrochloride

Virology 1969 37 632 641

10.1016/0042-6822(69)90281-5

52.

Lang

Narayan

Rouse

B.T.

Prevention of malignant avian influenza by 1-adamantanamine hydrochloride

Arch. Gesamte Virusforsch. 1970 32 171 184

10.1007/BF01249953

5501757

53.

Beard

C.W.

Brugh

Webster

R.G.

Emergence of amantadine-resistant H5N2 avian influenza virus during a simulated layer flock treatment program

Avian Dis. 1987 31 533 537

10.2307/1590736

54.

Webster

R.G.

Kawaoka

Bean

W.J.

Vaccination as a strategy to reduce the emergence of amantadine- and rimantadine-resistant strains of A/Chick/Pennsylvania/83 (H5N2) influenza virus

J. Antimicrob. Chemother. 1986 18 157 164

3793657

55.

Bean

W.J.

Threlkeld

S.C.

Webster

R.G.

Biologic potential of amantadine-resistant influenza-a virus in an avian model

J. Infect. Dis. 1989 159 1050 1056

10.1093/infdis/159.6.1050

2723453

56.

Bean

W.J.

Webster

R.G.

Biological properties of amantadine-resistant influenza-virus mutants

Antivir. Res. 1988 9 128 128 57.

Scholtissek

Faulkner

G.P.

Amantadine-resistant and -sensitive influenza A strains and recombinants

J. Gen. Virol. 1979 44 807 815

10.1099/0022-1317-44-3-807

58.

Bright

R.A.

Shay

D.K.

Shu

Cox

N.J.

Klimov

A.I.

Adamantane resistance among influenza A viruses isolated early during the 2005–2006 influenza season in the United States

JAMA 2006 295 891 894

10.1001/jama.295.8.joc60020

59.

Bright

R.A.

Medina

M.J.

Perez-Oronoz

Wallis

T.R.

Davis

X.M.

Povinelli

Cox

N.J.

Klimov

A.I.

Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: A cause for concern

Lancet 2005 366 1175 1181

10.1016/S0140-6736(05)67338-2

16198766

60.

Ilyushina

N.A.

Govorkova

E.A.

Webster

R.G.

Detection of amantadine-resistant variants among avian influenza viruses isolated in North America and Asia

Virology 2005 341 102 106

10.1016/j.virol.2005.07.003

16081121

61.

Cheung

C.L.

Rayner

J.M.

Smith

G.J.

Wang

Naipospos

T.S.

Zhang

Yuen

K.Y.

Webster

R.G.

Peiris

J.S.

Guan

Distribution of amantadine-resistant H5N1 avian influenza variants in Asia

J. Infect. Dis. 2006 193 1626 1629

10.1086/504723

62.

Qiao

Dong

Zhao

Tian

Amantadine-resistance among H5N1 avian influenza viruses isolated in Northern China

Antivir. Res. 2008 77 72 76

10.1016/j.antiviral.2007.08.007

17897729

63.

Lan

Zhang

Dong

Wang

Huang

Xin

Yang

Zhao

Wang

A comprehensive surveillance of adamantane resistance among human influenza A virus isolated from mainland China between 1956 and 2009

Antivir. Ther. 2010 15 853 859

10.3851/IMP1656

64.

Tosh

Murugkar

H.V.

Nagarajan

Tripathi

Katare

Jain

Khandia

Syed

Behera

Patil

Emergence of amantadine-resistant avian influenza H5N1 virus in India

Virus Gene. 2011 42 10 15

10.1007/s11262-010-0534-z

65.

Hurt

A.C.

Selleck

Komadina

Shaw

Brown

Barr

I.G.

Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes

Antivir. Res. 2007 73 228 231

10.1016/j.antiviral.2006.10.004

17112602

66.

Cyranoski

China's chicken farmers under fire for antiviral abuse

Nature 2005 435 1009

10.1038/4351009a

15973368

67.

Parry

Use of antiviral drug in poultry is blamed for drug resistant strains of avian flu

BMJ 2005 331 10

10.1136/bmj.331.7507.10

68.

Sipress

Bird flu drug rendered useless

The Washington Post 2005 June 18 A01 69.

Huang

Wen

Cao

Zhang

Khan

M.I.

Evolution analysis of the matrix (M) protein genes of 17 H9N2 chicken influenza viruses isolated in northern China during 1998–2008

Virus Gene. 2009 38 398 403

10.1007/s11262-009-0339-0

70.

Wainright

P.O.

Perdue

M.L.

Brugh

Beard

C.W.

Amantadine resistance among hemagglutinin subtype 5 strains of avian influenza virus

Avian Dis. 1991 35 31 39

10.2307/1591291

1827579

71. WHO

World Health Organisation: Use of antiviral drugs in poultry, a threat to their effectiveness for the treatment of human avian influenza

(accessed on 30 June 2012)

Available online:http://www.who.int/foodsafety/micro/avian_antiviral/en/print.html 72. CDC

Centers for Disease Control and Prevention: High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents—United States, 2005–06 influenza season

MMWR Morb. Mortal. Wkly. Rep. 2006 55 44 46

16424859

73.

Webster

R.G.

Kawaoka

Bean

W.J.

Beard

C.W.

Brugh

Chemotherapy and vaccination: A possible strategy for the control of highly virulent influenza virus

J. Virol. 1985 55 173 176

4009792

74.

Allen

U.D.

Aoki

F.Y.

Stiver

H.G.

The use of antiviral drugs for influenza: Recommended guidelines for practitioners

Can. J. Infect. Dis. Med. Microbiol. 2006 17 273 284

18382639

75.

McNicholl

I.R.

McNicholl

J.J.

Neuraminidase inhibitors: Zanamivir and oseltamivir

Ann. Pharmacother. 2001 35 57 70

10.1345/aph.10118

11197587

76.

Dreitlein

W.B.

Maratos

Brocavich

Zanamivir and oseltamivir: Two new options for the treatment and prevention of influenza

Clin. Therapeut. 2001 23 327 355

10.1016/S0149-2918(01)80042-4

77.

Ward

Small

Smith

Suter

Dutkowski

Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic

J. Antimicrob. Chemother. 2005 55 i5 i21

10.1093/jac/dki018

15709056

78.

Leneva

I.A.

Roberts

Govorkova

E.A.

Goloubeva

O.G.

Webster

R.G.

The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses

Antivir. Res. 2000 48 101 115

10.1016/S0166-3542(00)00123-6

11114412

79.

de Jong

M.D.

Tran

T.T.

Truong

H.K.

M.H.

Smith

G.J.

Nguyen

V.C.

Bach

V.C.

Phan

T.Q.

Q.H.

Guan

Oseltamivir resistance during treatment of influenza A (H5N1) infection

New Engl. J. Med. 2005 353 2667 2672

10.1056/NEJMoa054512

80.

McKimm-Breschkin

J.L.

Selleck

P.W.

Usman

T.B.

Johnson

M.A.

Reduced sensitivity of influenza A (H5N1) to oseltamivir

Emerg. Infect. Dis. 2007 13 1354 1357

10.3201/eid1309.07-0164

18252107

81.

Hill

A.W.

Guralnick

R.P.

Wilson

M.J.

Habib

Janies

Evolution of drug resistance in multiple distinct lineages of H5N1 avian influenza

Infect. Genet. Evol. 2009 9 169 178

10.1016/j.meegid.2008.10.006

82.

Earhart

K.C.

Elsayed

N.M.

Saad

M.D.

Gubareva

L.V.

Nayel

Deyde

V.M.

Abdelsattar

Abdelghani

A.S.

Boynton

B.R.

Mansour

M.M.

Oseltamivir resistance mutation N294S in human influenza A(H5N1) virus in Egypt

J. Infect. Publ. Health 2009 2 74 80

10.1016/j.jiph.2009.04.004

83.

Smith

J.R.

Oseltamivir in human avian influenza infection

J. Antimicrob. Chemother. 2010 65 ii25 ii33

10.1093/jac/dkq013

20215132

84.

Kayali

Webby

R.J.

Ducatez

M.F.

El Shesheny

R.A.

Kandeil

A.M.

Govorkova

E.A.

Mostafa

Ali

M.A.

The epidemiological and molecular aspects of influenza H5N1 viruses at the human-animal interface in Egypt

PLoS One 2011 6 e17730

10.1371/journal.pone.0017730

21445292

85.

Meijer

van der Goot

A.J.

Koch

van Bovenc

Kimman

T.G.

Oseltamivir reduces transmission, morbidity, and mortality of highly pathogenic avian influenza in chickens

Int. Congr. 2004 1263 495 498

10.1016/j.ics.2004.01.020

86.

Kaleta

E.F.

Blanco Pena

K.M.

Yilmaz

Redmann

Hofheinz

Avian influenza A viruses in birds of the order Psittaciformes: Reports on virus isolations, transmission experiments and vaccinations and initial studies on innocuity and efficacy of oseltamivir in ovo

DTW 2007 114 260 267 87.

Lee

D.H.

Lee

Y.N.

Park

J.K.

Yuk

S.S.

Lee

J.W.

Kim

J.I.

Han

J.S.

Lee

J.B.

Park

S.Y.

Choi

I.S.

Antiviral efficacy of oseltamivir against avian influenza virus in avian species

Avian Dis. 2011 55 677 679

10.1637/9725-031811-ResNote.1

88.

Yen

H.L.

Ilyushina

N.A.

Salomon

Hoffmann

Webster

R.G.

Govorkova

E.A.

Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo

J. Virol. 2007 81 12418 12426

10.1128/JVI.01067-07

89.

Orozovic

Lennerstrand

Olsen

Detection of resistance mutations to antivirals oseltamivir and zanamivir in avian influenza A viruses isolated from wild birds

PLoS One 2011 6 e16028

10.1371/journal.pone.0016028

21253602

90.

Moscona

Global transmission of oseltamivir-resistant influenza

New Engl. J. Med. 2009 360 953 956

10.1056/NEJMp0900648

19258250

91.

McKimm-Breschkin

Trivedi

Hampson

Hay

Klimov

Tashiro

Hayden

Zambon

Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir

Antimicrob. Agents Chemother. 2003 47 2264 2272

10.1128/AAC.47.7.2264-2272.2003

92.

Guralnik

Rosenbloom

R.A.

Petteruti

M.P.

Lefante

Limitations of current prophylaxis against influenza virus infection

Am. J. Therapeut. 2007 14 449 454

10.1097/MJT.0b013e3180a5e7d6

93.

Kitazato

Wang

Kobayashi

Viral infectious disease and natural products with antiviral activity

Drug Discov. Ther. 2007 1 14 22

22504360

94.

Wang

Jia

Zhao

Anti-influenza agents from plants and traditional Chinese medicine

Phytother. Res. 2006 20 335 341

10.1002/ptr.1892

95.

Guo

Pittler

M.H.

Ernst

Complementary medicine for treating or preventing influenza or influenza-like illness

Am. J. Med. 2007 120 923 929

10.1016/j.amjmed.2007.06.031

96.

Chen

Lim

C.E.

Kang

H.J.

Liu

Chinese herbal medicines for the treatment of type A H1N1 influenza: A systematic review of randomized controlled trials

PLoS One 2011 6 e28093

10.1371/journal.pone.0028093

22164232

97.

Nakayama

Suzuki

Toda

Okubo

Hara

Shimamura

Inhibition of the infectivity of influenza virus by tea polyphenols

Antivir. Res. 1993 21 289 299

10.1016/0166-3542(93)90008-7

8215301

98.

Kurokawa

Kumeda

C.A.

Yamamura

Kamiyama

Shiraki

Antipyretic activity of cinnamyl derivatives and related compounds in influenza virus-infected mice

Eur. J. Pharmacol. 1998 348 45 51

10.1016/S0014-2999(98)00121-6

99.

Mantani

Andoh

Kawamata

Terasawa

Ochiai

Inhibitory effect of Ephedrae herba, an oriental traditional medicine, on the growth of influenza A/PR/8 virus in MDCK cells

Antivir. Res. 1999 44 193 200

10.1016/S0166-3542(99)00067-4

10651070

100.

Mantani

Imanishi

Kawamata

Terasawa

Ochiai

Inhibitory effect of (+)-catechin on the growth of influenza A/PR/8 virus in MDCK cells

Planta Med. 2001 67 240 243

10.1055/s-2001-12009

11345695

101.

Imanishi

Tuji

Katada

Maruhashi

Konosu

Mantani

Terasawa

Ochiai

Additional inhibitory effect of tea extract on the growth of influenza A and B viruses in MDCK cells

Microbiol. Immunol. 2002 46 491 494

12222936

102.

Jung

S.K.

Han

D.U.

Kim

D.W.

Moon

W.K.

Chae

Antiviral effect of Saccharomyces cerevisiae beta-glucan to swine influenza virus by increased production of interferon-gamma and nitric oxide

J. Vet. Med. B 2004 51 72 76

10.1111/j.1439-0450.2004.00732.x

103.

Mak

N.K.

Leung

C.Y.

Wei

X.Y.

Shen

X.L.

Wong

R.N.

Leung

K.N.

Fung

M.C.

Inhibition of RANTES expression by indirubin in influenza virus-infected human bronchial epithelial cells

Biochem. Pharmacol. 2004 67 167 174

10.1016/j.bcp.2003.08.020

14667939

104.

Kubo

Nishimura

Antipyretic effect of Mao-to, a Japanese herbal medicine, for treatment of type A influenza infection in children

Phytomedicine 2007 14 96 101

10.1016/j.phymed.2006.09.015

105.

Miki

Nagai

Suzuki

Tsujimura

Koyama

Kinoshita

Furuhata

Yamada

Takahashi

Anti-influenza virus activity of biflavonoids

Bioorg. Med. Chem. Lett. 2007 17 772 775

10.1016/j.bmcl.2006.10.075

17110111

106.

Nagai

Miyaichi

Tomimori

Suzuki

Yamada

In vivo anti-influenza virus activity of plant flavonoids possessing inhibitory activity for influenza virus sialidase

Antivir. Res. 1992 19 207 217

10.1016/0166-3542(92)90080-O

107.

Kernan

M.R.

Sendl

Chen

J.L.

Jolad

S.D.

Blanc

Murphy

J.T.

Stoddart

C.A.

Nanakorn

Balick

M.J.

Rozhon

E.J.

Two new lignans with activity against influenza virus from the medicinal plant Rhinacanthus nasutus

J. Nat. Prod. 1997 60 635 637

10.1021/np960613i

9214738

108.

Quan

F.S.

Compans

R.W.

Cho

Y.K.

Kang

S.M.

Ginseng and Salviae herbs play a role as immune activators and modulate immune responses during influenza virus infection

Vaccine 2007 25 272 282

10.1016/j.vaccine.2006.07.041

109.

Deryabin

P.G.

Lvov

D.K.

Botikov

A.G.

Ivanov

Kalinovsky

Niedzwiecki

Rath

Effects of a nutrient mixture on infectious properties of the highly pathogenic strain of avian influenza virus A/H5N1

Biofactors 2008 33 85 97

10.1002/biof.5520330201

19346584

110.

Geng

Shaozhong

Shaohua

Ziren

Xiaoping

Experimental study on the antivirus effect of Zhongsheng pills on influenza virus H5N1

World Sci. Tech. 2009 11 365 370

10.1016/S1876-3553(10)60017-8

111.

Pleschka

Stein

Schoop

Hudson

J.B.

Anti-viral properties and mode of action of standardized Echinacea purpurea extract against highly pathogenic avian influenza virus (H5N1, H7N7) and swine-origin H1N1 (S-OIV)

Virol. J. 2009 6 197

10.1186/1743-422X-6-197

112.

Shin

W.J.

Lee

K.H.

Park

M.H.

Seong

B.L.

Broad-spectrum antiviral effect of Agrimonia pilosa extract on influenza viruses

Microbiol. Immunol. 2010 54 11 19

10.1111/j.1348-0421.2009.00173.x

20055938

113.

Sundararajan

Ganapathy

Huan

Dunlap

J.R.

Webby

R.J.

Kotwal

G.J.

Sangster

M.Y.

Influenza virus variation in susceptibility to inactivation by pomegranate polyphenols is determined by envelope glycoproteins

Antivir. Res. 2010 88 1 9

10.1016/j.antiviral.2010.06.014

114.

Han

Wang

Gao

Anti-influenza virus effect of aqueous extracts from dandelion

Virol. J. 2011 8 538

10.1186/1743-422X-8-538

22168277

115.

Garozzo

Timpanaro

Stivala

Bisignano

Castro

Activity of Melaleuca alternifolia (tea tree) oil on Influenza virus A/PR/8: Study on the mechanism of action

Antivir. Res. 2011 89 83 88

10.1016/j.antiviral.2010.11.010

21095205

116.

Glatthaar-Saalmuller

Rauchhaus

Rode

Haunschild

Saalmuller

Antiviral activity in vitro of two preparations of the herbal medicinal product Sinupret(R) against viruses causing respiratory infections

Phytomedicine 2011 19 1 7

10.1016/j.phymed.2011.10.010

117.

Zhang

Cheng

Y.X.

Liu

A.L.

Wang

H.D.

Wang

Y.L.

G.H.

Antioxidant, anti-inflammatory and anti-influenza properties of components from Chaenomeles speciosa

Molecules 2010 15 8507 8517

10.3390/molecules15118507

21102377

118.

Kwon

H.J.

Kim

H.H.

Yoon

S.Y.

Ryu

Y.B.

Chang

J.S.

Cho

K.O.

Rho

M.C.

Park

S.J.

Lee

W.S.

In vitro inhibitory activity of Alpinia katsumadai extracts against influenza virus infection and hemagglutination

Virol. J. 2010 7 307

10.1186/1743-422X-7-307

119.

J.Q.

Kim

Y.J.

Wang

Hao

In vivo and in vitro antiviral effects of berberine on influenza virus

Chin. J. Integr. Med. 2011 17 444 452

10.1007/s11655-011-0640-3

120.

Shaukat

T.M.

Ashraf

Omer

M.O.

Rasheed

M.A.

Muhammad

Shaukat

T.M.

Younus

Shahzad

M.K.

Comparative efficacy of various antiviral agents against avian influenza virus (Type H7N3/Pakistan/2003)

Pakistan J. Zool. 2011 43 849 854 121.

Mehrbod

Ideris

Omar

A.R.

Hair-Bejo

Tan

S.W.

Kheiri

M.T.

Tabatabaian

Attenuation of influenza virus infectivity with herbal-marine compound (HESA-A): An in vitro study in MDCK cells

Virol. J. 2012 9 44

10.1186/1743-422X-9-44

122.

Sriwilaijaroen

Fukumoto

Kumagai

Hiramatsu

Odagiri

Tashiro

Suzuki

Antiviral effects of Psidium guajava Linn. (guava) tea on the growth of clinical isolated H1N1 viruses: Its role in viral hemagglutination and neuraminidase inhibition

Antivir. Res. 2012 94 139 146

10.1016/j.antiviral.2012.02.013

22453134

123.

Yang

Zhou

Liu

Zheng

In vitro anti-influenza virus and anti-inflammatory activities of theaflavin derivatives

Antivir. Res. 2012 94 217 224

10.1016/j.antiviral.2012.04.001

22521753

124.

Garozzo

Timpanaro

Bisignano

Furneri

P.M.

Bisignano

Castro

In vitro antiviral activity of Melaleuca alternifolia essential oil

Lett. Appl. Microbiol. 2009 49 806 808

10.1111/j.1472-765X.2009.02740.x

125.

Hudson

J.B.

The use of herbal extracts in the control of influenza

J. Med. Plants Res. 2009 3 1189 1195 126.

Krawitz

Mraheil

M.A.

Stein

Imirzalioglu

Domann

Pleschka

Hain

Inhibitory activity of a standardized elderberry liquid extract against clinically-relevant human respiratory bacterial pathogens and influenza A and B viruses

BMC Compl. Alternative Med. 2011 11 16

10.1186/1472-6882-11-16

127.

Sood

Swarup

Bhatia

Kulkarni

D.D.

Dey

Saini

Dubey

S.C.

Antiviral activity of crude extracts of Eugenia jambolana Lam. against highly pathogenic avian influenza (H5N1) virus

Indian J. Exp. Biol. 2012 50 179 186

22439432

128.

Gangopadhyay

Ganguli

Datta

Inhibiting H5N1 hemagglutinin with samll molecule ligands

Int. J. Bioinformatics Res. 2011 3 185 189 129.

Shang

R.-F.

Liang

J.-P.

Z.-Y.

Yang

H.-J.

Hua

L.-Y.

Guo

W.-Z.

Cui

Wang

In vivo inhibition of NAS preparation on H9N2 subtype AIV

Virol. Sin. 2010 25 145 150

10.1007/s12250-010-3082-8

130.

Barbour

E.K.

Saadé

M.F.

Abdel Nour

A.M.

Kayali

Kidess

Bou Ghannam

Harakeh

Shaib

Evaluation of essential oils in the treatment of broilers co-infected with multiple respiratory etiologic agents

Int. J. Appl. Res. Vet. Med. 2011 9 317 323 131.

Barbour

E.K.

El-Hakim

R.G.

Kaadi

M.S.

Shaib

H.A.

Gerges

D.D.

Nehme

P.A.

Evaluation of the histopathology of the respiratory system in essential oil-treated broilers following a challenge with Mycoplasma gallisepticum and/or H9N2 influenza virus

Int. J. Appl. Res. Vet. Med. 2006 4 293 300 132.

Lee

H.J.

Lee

Y.N.

Youn

H.N.

Lee

D.H.

Kwak

J.H.

Seong

B.L.

Lee

J.B.

Park

S.Y.

Choi

I.S.

Song

C.S.

Anti-influenza virus activity of green tea by-products in vitro and efficacy against influenza virus infection in chickens

Poultry Sci. 2012 91 66 73

10.3382/ps.2011-01645

133.

Song

J.M.

Lee

K.H.

Seong

B.L.

Antiviral effect of catechins in green tea on influenza virus

Antivir. Res. 2005 68 66 74

10.1016/j.antiviral.2005.06.010

16137775

134.

Liu

Guo

Wang

Zhang

Liu

Higgins

Walsh

Shanahan-Prendergast

Evaluation of the efficacy and safety of a statin/caffeine combination against H5N1, H3N2 and H1N1 virus infection in BALB/c mice

Eur. J. Pharmaceut. Sci. 2009 38 215 223

10.1016/j.ejps.2009.07.004

135.

Zhai

Wang

Enhancement of humoral immune responses to inactivated Newcastle disease and avian influenza vaccines by oral administration of ginseng stem-and-leaf saponins in chickens

Poultry Sci. 2011 90 1955 1959

10.3382/ps.2011-01433

136.

Jiang

Liu

Zheng

Immune regulation of avian influenza vaccine in hens using Hypericum perforatum L. methanol extraction

Plant Omics 2012 5 40 45 137.

Landy

Ghalamkari

G.H.

Toghyani

Evaluation of St John's Wort (Hypericum perforatum L.) as an antibiotic growth promoter substitution on performance, carcass characteristics, some of the immune responses, and serum biochemical parameters of broiler chicks

J. Med. Plants Res. 2012 6 510 515 138.

Rajput

Z.I.

Xiao

C.W.

S.H.

Arijo

A.G.

Soomro

N.M.

Improvement of the efficacy of influenza vaccination (H5N1) in chicken by using extract of Cochinchina momordica seed (ECMS)

J. Zhejiang Univ. Sci. B. 2007 8 331 337

17542061

139.

Liu

F.X.

Sun

Cui

Z.Z.

Analysis of immunological enhancement of immunosuppressed chickens by Chinese herbal extracts

J. Ethnopharmacol. 2010 127 251 256

10.1016/j.jep.2009.11.012

140.

Jafari

R.A.

Ghorbanpoor

Hoshmand Diarjan

Study on immunomodulatory activity of dietary garlic in chickens vaccinated against avian influenza virus (subtype H9N2)

Int. J. Poultry Sci. 2009 8 401 403

10.3923/ijps.2009.401.403

141.

Kurokawa

Watanabe

Shimizu

Sawamura

Shiraki

Modulation of cytokine production by 7-hydroxycoumarin in vitro and its efficacy against influenza infection in mice

Antivir. Res. 2010 85 373 380

10.1016/j.antiviral.2009.11.001

19913056

142.

Fusco

Liu

X.Y.

Savage

Taur

Xiao

W.L.

Kennelly

Yuan

J.D.

Cassileth

Salvatore

Papanicolaou

G.A.

Echinacea purpurea aerial extract alters course of influenza infection in mice

Vaccine 2010 28 3956 3962

10.1016/j.vaccine.2010.03.047

20382242

143.

Hori

Kiyoshima

Shida

Yasui

Effect of intranasal administration of Lactobacillus casei Shirota on influenza virus infection of upper respiratory tract in mice

Clin. Diagn. Lab. Immunol. 2001 8 593 597

11329464

144.

Yasui

Kiyoshima

Hori

Reduction of influenza virus titer and protection against influenza virus infection in infant mice fed Lactobacillus casei Shirota

Clin. Diagn. Lab. Immunol. 2004 11 675 679

15242940

145.

Olivares

Diaz-Ropero

M.P.

Sierra

Lara-Villoslada

Fonolla

Navas

Rodriguez

J.M.

Xaus

Oral intake of Lactobacillus fermentum CECT5716 enhances the effects of influenza vaccination

Nutrition 2007 23 254 260

10.1016/j.nut.2007.01.004

146.

Boge

Remigy

Vaudaine

Tanguy

Bourdet-Sicard

van der Werf

A probiotic fermented dairy drink improves antibody response to influenza vaccination in the elderly in two randomised controlled trials

Vaccine 2009 27 5677 5684

10.1016/j.vaccine.2009.06.094

19615959

147.

Harata

Hiruta

Kawase

Kubota

Hiramatsu

Yausi

Intranasal administration of Lactobacillus rhamnosus GG protects mice from H1N1 influenza virus infection by regulating respiratory immune responses

Lett. Appl. Microbiol. 2010 50 597 602

10.1111/j.1472-765X.2010.02844.x

148.

Davidson

L.E.

Fiorino

A.M.

Snydman

D.R.

Hibberd

P.L.

Lactobacillus GG as an immune adjuvant for live-attenuated influenza vaccine in healthy adults: A randomized double-blind placebo-controlled trial

Eur. J. Clin. Nutr. 2011 65 501 507

10.1038/ejcn.2010.289

21285968

149.

Rizzardini

Eskesen

Calder

P.C.

Capetti

Jespersen

Clerici

Evaluation of the immune benefits of two probiotic strains Bifidobacterium animalis ssp. lactis, BB-12(R) and Lactobacillus paracasei ssp. paracasei, L. casei 431(R) in an influenza vaccination model: A randomised, double-blind, placebo-controlled study

Br. J. Nutr. 2012 107 876 884

10.1017/S000711451100420X

150.

Iwabuchi

Xiao

J.Z.

Yaeshima

Iwatsuki

Oral administration of Bifidobacterium longum ameliorates influenza virus infection in mice

Biol. Pharmaceut. Bull. 2011 34 1352 1355

10.1248/bpb.34.1352

151.

Kawase

Kubota

Yoda

Miyazawa

Hiramatsu

Heat-killed Lactobacillus gasseri TMC0356 protects mice against influenza virus infection by stimulating gut and respiratory immune responses

FEMS Immunol. Med. Microbiol. 2012 64 280 288

10.1111/j.1574-695X.2011.00903.x

152.

Takeda

Takeshita

Kikuchi

Dashnyam

Kawahara

Yoshida

Watanabe

Muguruma

Kurokawa

Efficacy of oral administration of heat-killed probiotics from Mongolian dairy products against influenza infection in mice: Alleviation of influenza infection by its immunomodulatory activity through intestinal immunity

Int. Immunopharm. 2011 11 1976 1983

10.1016/j.intimp.2011.08.007

153.

Patterson

J.A.

Burkholder

K.M.

Application of prebiotics and probiotics in poultry production

Poultry Sci. 2003 82 627 631 154.

Nava

G.M.

Bielke

L.R.

Callaway

T.R.

Castaneda

M.P.

Probiotic alternatives to reduce gastrointestinal infections: The poultry experience

Anim. Health Res. Rev. 2005 6 105 118

10.1079/AHR2005103

155.

Lutful Kabir

S.M.

The role of probiotics in the poultry industry

Int. J. Mol. Sci. 2009 10 3531 3546

10.3390/ijms10083531

20111681

156.

Chon

Choi

Jeong

Evaluation system for an experimental study of low-pathogenic avian influenza virus (H9N2) infection in specific pathogen free chickens using lactic acid bacteria, Lactobacillus plantarum KFCC11389P

Avian Pathol. 2008 37 593 597

10.1080/03079450802439056

157.

Seo

B.J.

Rather

I.A.

Kumar

V.J.

Choi

U.H.

Moon

M.R.

Lim

J.H.

Park

Y.H.

Evaluation of Leuconostoc mesenteroides YML003 as a probiotic against low-pathogenic avian influenza (H9N2) virus in chickens

J. Appl. Microbiol. 2012 113 163 171

10.1111/j.1365-2672.2012.05326.x

22548634

158.

Ghafoor

Naseem

Younus

Nazir

Immunomodulatory effects of multistrain probiotics (Protexin™) on broiler chicken vaccinated against avian influenza virus (H9)

Int. J. Poultry Sci. 2005 4 777 780

10.3923/ijps.2005.777.780

159.

Lei

Chen

Wei

Lam

D.M.

Immunoprotection against influenza H5N1 virus by oral administration of enteric-coated recombinant Lactococcus lactis mini-capsules

Virology 2010 407 319 324

10.1016/j.virol.2010.08.007

20850860

160.

Wang

Gao

Yang

Mucosal and systemic immune responses induced by recombinant Lactobacillus spp. expressing the hemagglutinin of the avian influenza virus H5N1

Clin. Vaccine Immunol. 2012 19 174 179

10.1128/CVI.05618-11

161.

Novak

Ester

Savic

Sekellick

M.J.

Marcus

P.I.

Lowenthal

J.W.

Vainio

Ragland

W.L.

Immune status assessment by abundance of IFN-alpha and IFN-gamma mRNA in chicken blood

J. Interferon Cytokine Res. 2001 21 643 651

10.1089/10799900152547911

11559443

162.

Sekellick

M.J.

Ferrandino

A.F.

Hopkins

D.A.

Marcus

P.I.

Chicken interferon gene: Cloning, expression, and analysis

J. Interferon Res. 1994 14 71 79

10.1089/jir.1994.14.71

163.

Lukacsi

Molnar

Siroki

Rosztoczy

Combined effects of amantadine and interferon on influenza virus replication in chicken and human embryo trachea organ culture

Acta Microbiol. Hung. 1985 32 357 362

3835778

164.

Marcus

P.I.

Girshick

van der Heide

Sekellick

M.J.

Super-sentinel chickens and detection of low-pathogenicity influenza virus

Emerg. Infect. Dis. 2007 13 1608 1610

10.3201/eid1310.061552

165.

Song

Zhao

D.G.

Y.J.

Transient expression of chicken alpha interferon gene in lettuce

J. Zhejiang Univ. Sci. B. 2008 9 351 355

18500773

166.

Meng

Yang

Qin

Wang

Sun

Liu

Recombinant chicken interferon-alpha inhibits H9N2 avian influenza virus replication in vivo by oral administration

J. Interferon Cytokine Res. 2011 31 533 538

10.1089/jir.2010.0123

167.

Wei

Peng

G.Q.

Jin

M.L.

Zhu

Y.D.

Zhou

H.B.

Guo

H.Y.

Chen

H.C.

Cloning, prokaryotic expression of chicken interferon-alpha gene and study on antiviral effect of recombinant chicken interferon-alpha

Chin. J. Biotechnol. 2006 22 737 743 168.

Reemers

S.S.

van Haarlem

D.A.

Groot Koerkamp

M.J.

Vervelde

Differential gene-expression and host-response profiles against avian influenza virus within the chicken lung due to anatomy and airflow

J. Gen. Virol. 2009 90 2134 2146

10.1099/vir.0.012401-0

169.

Sekellick

M.J.

Carra

S.A.

Bowman

Hopkins

D.A.

Marcus

P.I.

Transient resistance of influenza virus to interferon action attributed to random multiple packaging and activity of NS genes

J. Interferon Cytokine Res. 2000 20 963 970

10.1089/10799900050198408

11096453

170.

Xia

Liu

Z.G.

Lin

C.Y.

Wang

The interferon-alpha genes from three chicken lines and its effects on H9N2 influenza viruses

Anim. Biotechnol. 2004 15 77 88

10.1081/ABIO-120037900

171.

Rahman

M.M.

Uyangaa

Han

Y.W.

Kim

S.B.

Kim

J.H.

Choi

J.Y.

S.K.

Oral co-administration of live attenuated Salmonella enterica serovar Typhimurium expressing chicken interferon-alpha and interleukin-18 enhances the alleviation of clinical signs caused by respiratory infection with avian influenza virus H9N2

Vet. Microbiol. 2012 157 448 455

10.1016/j.vetmic.2011.12.029

22245401

172.

Rahman

M.M.

Uyangaa

Han

Y.W.

Kim

S.B.

Kim

J.H.

Choi

J.Y.

Yoo

D.J.

Hong

J.T.

Han

S.B.

Kim

Oral administration of live attenuated Salmonella enterica serovar Typhimurium expressing chicken interferon-alpha alleviates clinical signs caused by respiratory infection with avian influenza virus H9N2

Vet. Microbiol. 2011 154 140 151

10.1016/j.vetmic.2011.06.034

173.

Chen

H.Y.

Shang

Y.H.

Yao

H.X.

Cui

B.A.

Zhang

H.Y.

Wang

Z.X.

Wang

Y.D.

Chao

A.J.

Duan

T.Y.

Immune responses of chickens inoculated with a recombinant fowlpox vaccine coexpressing HA of H9N2 avain influenza virus and chicken IL-18

Antivir. Res. 2011 91 50 56

10.1016/j.antiviral.2011.04.007

21549153

174.

Mingxiao

Ningyi

Zhenguo

Ruilin

Dongliang

Min

Gefen

Chang

Leili

Kuoshi

Construction and immunogenicity of recombinant fowlpox vaccines coexpressing HA of AIV H5N1 and chicken IL18

Vaccine 2006 24 4304 4311

10.1016/j.vaccine.2006.03.006

16621199

175.

Chen

H.Y.

Cui

B.A.

Xia

P.A.

X.S.

G.Z.

Yang

M.F.

Zhang

H.Y.

Wang

X.B.

Cao

S.F.

Zhang

L.X.

Cloning, in vitro expression and bioactivity of duck interleukin-18

Vet. Immunol. Immunopathol. 2008 123 205 214

10.1016/j.vetimm.2008.01.036

176.

Zhou

J.Y.

Wang

J.Y.

Chen

J.G.

J.X.

Gong

Teng

Q.Y.

Guo

J.Q.

Shen

H.G.

Cloning, in vitro expression and bioactivity of duck interleukin-2

Mol. Immunol. 2005 42 589 598

10.1016/j.molimm.2004.09.014

177.

Zhou

J.Y.

Chen

J.G.

Wang

J.Y.

J.X.

Gong

cDNA cloning and functional analysis of goose interleukin-2

Cytokine 2005 30 328 338

10.1016/j.cyto.2004.12.015

15935953

178.

Wong

J.P.

Christopher

M.E.

Viswanathan

Dai

Salazar

A.M.

Sun

L.Q.

Wang

Antiviral role of toll-like receptor-3 agonists against seasonal and avian influenza viruses

Curr. Pharmaceut. Des. 2009 15 1269 1274

10.2174/138161209787846775

179.

Wong

J.P.

Christopher

M.E.

Viswanathan

Karpoff

Dai

Das

Sun

L.Q.

Wang

Salazar

A.M.

Activation of toll-like receptor signaling pathway for protection against influenza virus infection

Vaccine 2009 27 3481 3483

10.1016/j.vaccine.2009.01.048

19200852

180.

Stewart

C.R.

Bagnaud-Baule

Karpala

A.J.

Lowther

Mohr

P.G.

Wise

T.G.

Lowenthal

J.W.

Bean

A.G.

Toll-like receptor 7 ligands inhibit influenza A infection in chickens

J. Interferon Cytokine Res. 2012 32 46 51

10.1089/jir.2011.0036

21929369

181.

Jenkins

K.A.

Lowenthal

J.W.

Kimpton

Bean

A.G.

The in vitro and in ovo responses of chickens to TLR9 subfamily ligands

Dev. Comp. Immunol. 2009 33 660 667

10.1016/j.dci.2008.11.009

182.

Stram

Kuzntzova

Inhibition of viruses by RNA interference

Virus Gene. 2006 32 299 306

10.1007/s11262-005-6914-0

183.

Filip

Bai

Nguyen

Eisen

H.N.

Chen

Inhibition of influenza virus production in virus-infected mice by RNA interference

Proc. Natl. Acad. Sci. U. S. A. 2004 101 8676 8681

10.1073/pnas.0402486101

15173599

184.

McManus

M.T.

Nguyen

Shen

C.H.

Sharp

P.A.

Eisen

H.N.

Chen

RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription

Proc. Natl. Acad. Sci. U. S. A. 2003 100 2718 2723

10.1073/pnas.0437841100

12594334

185.

Sui

H.Y.

Zhao

G.Y.

Huang

J.D.

Jin

D.Y.

Yuen

K.Y.

Zheng

B.J.

Small interfering RNA targeting m2 gene induces effective and long term inhibition of influenza A virus replication

PLoS One 2009 4 e5671

10.1371/journal.pone.0005671

19479060

186.

Zhou

Duan

RNA interference of avian influenza virus H5N1 by inhibiting viral mRNA with siRNA expression plasmids

J. Biotechnol. 2008 135 140 144

10.1016/j.jbiotec.2008.03.007

18456361

187.

Hui

E.K.

Yap

E.M.

D.S.

Chen

I.S.

Nayak

D.P.

Inhibition of influenza virus matrix (M1) protein expression and virus replication by U6 promoter-driven and lentivirus-mediated delivery of siRNA

J. Gen. Virol. 2004 85 1877 1884

10.1099/vir.0.79906-0

15218172

188.

Tompkins

S.M.

C.Y.

Tumpey

T.M.

Epstein

S.L.

Protection against lethal influenza virus challenge by RNA interference in vivo

Proc. Natl. Acad. Sci. U. S. A. 2004 101 8682 8686

10.1073/pnas.0402630101

189.

Zhang

Wang

C.Y.

Yang

S.T.

Qin

J.L.

Xia

X.Z.

Inhibition of highly pathogenic avian influenza virus H5N1 replication by the small interfering RNA targeting polymerase A gene

Biochem. Biophys. Res. Comm. 2009 390 421 426

10.1016/j.bbrc.2009.09.039

19755113

190.

Zhou

Jin

Peng

Liu

Cao

Chen

Effective small interfering RNAs targeting matrix and nucleocapsid protein gene inhibit influenza A virus replication in cells and mice

Antivir. Res. 2007 76 186 193

10.1016/j.antiviral.2007.07.002

17719657

191.

Y.C.

Kong

L.H.

Cheng

B.Z.

K.S.

Construction of influenza virus siRNA expression vectors and their inhibitory effects on multiplication of influenza virus

Avian Dis. 2005 49 562 573

10.1637/7365-041205R2.1

192.

Abrahamyan

Nagy

Golovan

S.P.

Human H1 promoter expressed short hairpin RNAs (shRNAs) suppress avian influenza virus replication in chicken CH-SAH and canine MDCK cells

Antivir. Res. 2009 84 159 167

10.1016/j.antiviral.2009.08.009

19737578

193.

Bennink

J.R.

Palmore

T.N.

The promise of siRNAs for the treatment of influenza

Trends Mol. Med. 2004 10 571 574

10.1016/j.molmed.2004.10.004

15567323

194.

Suzuki

Saitoh

Suzuki

Takaku

Inhibition of influenza virus by baculovirus-mediated shRNA

Nucleic Acids Symp. Ser. (Oxf) 2009 53 287 288

10.1093/nass/nrp144

195.

Eisen

H.N.

Chen

Use of siRNAs to prevent and treat influenza virus infection

Virus Res. 2004 102 37 42

10.1016/j.virusres.2004.01.013

15068878

196.

McSwiggen

J.A.

Seth

A potential treatment for pandemic influenza using siRNAs targeting conserved regions of influenza A

Expet Opin. Biol. Ther. 2008 8 299 313

10.1517/14712598.8.3.299

197.

Elbashir

S.M.

Harborth

Lendeckel

Yalcin

Weber

Tuschl

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

Nature 2001 411 494 498

10.1038/35078107

198.

Wadhwa

Kaul

S.C.

Miyagishi

Taira

Know-how of RNA interference and its applications in research and therapy

Mutat. Res. 2004 567 71 84

10.1016/j.mrrev.2004.06.002

15341903

199.

Aigner

Gene silencing through RNA interference (RNAi) in vivo: Strategies based on the direct application of siRNAs

J. Biotechnol. 2006 124 12 25

10.1016/j.jbiotec.2005.12.003

200.

Morris

K.V.

Rossi

J.J.

Lentivirus-mediated RNA interference therapy for human immunodeficiency virus type 1 infection

Hum. Gene Ther. 2006 17 479 486

10.1089/hum.2006.17.479

16716105

201.

Thomas

J.J.

Klibanov

A.M.

Chen

Polycation-mediated delivery of siRNAs for prophylaxis and treatment of influenza virus infection

Expet Opin. Biol. Ther. 2005 5 495 505

10.1517/14712598.5.4.495

202.

O'Neill

Australia tackles bird flu using RNAi

Nat. Biotechnol. 2007 25 605 606

17557083

10.1038/nbt0607-605

203.

Horby

Nguyen

N.Y.

Dunstan

S.J.

Baillie

J.K.

The role of host genetics in susceptibility to influenza: A systematic review

PLoS One 2012 7 e33180

10.1371/journal.pone.0033180

22438897

204.

Zekarias

Ter Huurne

A.A.

Landman

W.J.

Rebel

J.M.

Pol

J.M.

Gruys

Immunological basis of differences in disease resistance in the chicken

Vet. Res. 2002 33 109 125

10.1051/vetres:2002001

11944802

205.

Sironi

Williams

J.L.

Moreno-Martin

A.M.

Ramelli

Stella

Jianlin

Weigend

Lombardi

Cordioli

Mariani

Susceptibility of different chicken lines to H7N1 highly pathogenic avian influenza virus and the role of Mx gene polymorphism coding amino acid position 631

Virology 2008 380 152 156

10.1016/j.virol.2008.07.022

206.

Swayne

D.E.

Radin

M.J.

Hoepf

T.M.

Slemons

R.D.

Acute renal failure as the cause of death in chickens following intravenous inoculation with avian influenza virus A/chicken/Alabama/7395/75 (H4N8)

Avian Dis. 1994 38 151 157

10.2307/1591849

8002884

207.

Thomas

Manin

T.B.

Andriyasov

A.V.

Swayne

D.E.

Limited susceptibility and lack of systemic infection by an H3N2 swine influenza virus in intranasally inoculated chickens

Avian Dis. 2008 52 498 501

10.1637/8210-011408-RESNOTE.1

208.

Gharaibeh

Pathogenicity of an avian influenza virus serotype H9N2 in chickens

Avian Dis. 2008 52 106 110

10.1637/8108-090907-Reg

18459305

209.

Keawcharoen

van Riel

van Amerongen

Bestebroer

Beyer

W.E.

van Lavieren

Osterhaus

A.D.

Fouchier

R.A.

Kuiken

Wild ducks as long-distance vectors of highly pathogenic avian influenza virus (H5N1)

Emerg. Infect. Dis. 2008 14 600 607

10.3201/eid1404.071016

18394278

210.

Munster

V.J.

Baas

Lexmond

Waldenstrom

Wallensten

Fransson

Rimmelzwaan

G.F.

Beyer

W.E.

Schutten

Olsen

Spatial, temporal, and species variation in prevalence of influenza A viruses in wild migratory birds

PLoS Pathog. 2007 3 e61

10.1371/journal.ppat.0030061

211.

Brown

J.D.

Stallknecht

D.E.

Beck

J.R.

Suarez

D.L.

Swayne

D.E.

Susceptibility of North American ducks and gulls to H5N1 highly pathogenic avian influenza viruses

Emerg. Infect. Dis. 2006 12 1663 1670

10.3201/eid1211.060652

17283615

212.

Ruff

Interferon-mediated development of influenza virus resistance in hybrids between Mx gene-bearing and control mouse embryo fibroblasts

J. Gen. Virol. 1983 64 1291 1300

10.1099/0022-1317-64-6-1291

213.

Staeheli

Haller

Boll

Lindenmann

Weissmann

Mx protein: Constitutive expression in 3T3 cells transformed with cloned Mx cDNA confers selective resistance to influenza virus

Cell 1986 44 147 158

10.1016/0092-8674(86)90493-9

3000619

214.

Chang

K.C.

Goldspink

Lida

Studies in the in vivo expression of the influenza resistance gene Mx by in-situ hybridisation

Arch. Virol. 1990 110 151 164

10.1007/BF01311285

215.

Meier

Kunz

Haller

Arnheiter

Activity of rat Mx proteins against a rhabdovirus

J. Virol. 1990 64 6263 6269

2173790

216.

Salomon

Staeheli

Kochs

Yen

H.L.

Franks

Rehg

J.E.

Webster

R.G.

Hoffmann

Mx1 gene protects mice against the highly lethal human H5N1 influenza virus

Cell Cycle 2007 6 2417 2421

10.4161/cc.6.19.4779

217.

Haller

Staeheli

Kochs

Protective role of interferon-induced Mx GTPases against influenza viruses

Rev. Sci. Tech. 2009 28 219 231

19618628

218.

Pavlovic

Zurcher

Haller

Staeheli

Resistance to influenza virus and vesicular stomatitis virus conferred by expression of human MxA protein

J. Virol. 1990 64 3370 3375

2161946

219.

J.H.

Jin

H.K.

Asano

Takada

Ninomiya

Kida

Hokiyama

Ohara

Tsuzuki

Nishibori

Polymorphisms and the differential antiviral activity of the chicken Mx gene

Genome Res. 2002 12 595 601

11932243

220.

X.Y.

L.J.

Yao

J.F.

Yang

Skewed allele frequencies of an Mx gene mutation with potential resistance to avian influenza virus in different chicken populations

Poultry Sci. 2006 85 1327 1329 221.

X.Y.

L.J.

Hou

Z.C.

Yao

J.F.

G.Y.

Yang

Genomic structure and diversity of the chicken Mx gene

Poultry Sci. 2007 86 786 789 222.

Watanabe

Polymorphisms of the chicken antiviral MX gene

Cytogenet. Genome Res. 2007 117 370 375

10.1159/000103200

17675880

223.

Sartika

Sulandari

Zein

M.S.

Selection of Mx gene genotype as genetic marker for Avian Influenza resistance in Indonesian native chicken

BMC Proc. 2011 5 S37

22373110

224.

Dillon

Runstadler

Mx gene diversity and influenza association among five wild dabbling duck species (Anas spp.) in Alaska

Infect. Genet. Evol. 2010 10 1085 1093

10.1016/j.meegid.2010.07.004

225.

Berlin

Yang

Ellegren

Positive diversifying selection in avian Mx genes

Immunogenetics 2008 60 689 697

10.1007/s00251-008-0324-0

18726592

226.

Yin

C.G.

Zhang

C.S.

Zhang

A.M.

Qin

H.W.

Wang

X.Q.

L.X.

Zhao

G.P.

Expression analyses and antiviral properties of the Beijing-You and White Leghorn myxovirus resistance gene with different amino acids at position 631

Poultry Sci. 2010 89 2259 2264

10.3382/ps.2010-00826

227.

Seyama

J.H.

Ohe

Sasaoka

Okada

Gomi

Yoneda

Ueda

Nishibori

Okamoto

Population research of genetic polymorphism at amino acid position 631 in chicken Mx protein with differential antiviral activity

Biochem. Genet. 2006 44 437 448

16955367

228.

Balkissoon

Staines

McCauley

Wood

Young

Kaufman

Butter

Low frequency of the Mx allele for viral resistance predates recent intensive selection in domestic chickens

Immunogenetics 2007 59 687 691

10.1007/s00251-007-0235-5

229.

Bazzigher

Schwarz

Staeheli

No enhanced influenza virus resistance of murine and avian cells expressing cloned duck Mx protein

Virology 1993 195 100 112

10.1006/viro.1993.1350

8100373

230.

Schumacher

Bernasconi

Schultz

Staeheli

The chicken Mx promoter contains an ISRE motif and confers interferon inducibility to a reporter gene in chick and monkey cells

Virology 1994 203 144 148

10.1006/viro.1994.1464

231.

Ewald

S.J.

Kapczynski

D.R.

Livant

E.J.

Suarez

D.L.

Ralph

McLeod

Miller

Association of Mx1 Asn631 variant alleles with reductions in morbidity, early mortality, viral shedding, and cytokine responses in chickens infected with a highly pathogenic avian influenza virus

Immunogenetics 2011 63 363 375

10.1007/s00251-010-0509-1

232.

Benfield

C.T.

Lyall

J.W.

Kochs

Tiley

L.S.

Asparagine 631 variants of the chicken Mx protein do not inhibit influenza virus replication in primary chicken embryo fibroblasts or in vitro surrogate assays

J. Virol. 2008 82 7533 7539

10.1128/JVI.00185-08

233.

Benfield

C.T.

Lyall

J.W.

Tiley

L.S.

The cytoplasmic location of chicken mx is not the determining factor for its lack of antiviral activity

PLoS One 2010 5 e12151

10.1371/journal.pone.0012151

20808435

234.

Schusser

Reuter

von der Malsburg

Penski

Weigend

Kaspers

Staeheli

Hartle

Mx is dispensable for interferon-mediated resistance of chicken cells against influenza A virus

J. Virol. 2011 85 8307 8315

10.1128/JVI.00535-11

21632756

235.

Bernasconi

Schultz

Staeheli

The interferon-induced Mx protein of chickens lacks antiviral activity

J. Interferon Cytokine Res. 1995 15 47 53

10.1089/jir.1995.15.47

7648434

236.

Sironi

Williams

J.L.

Stella

Minozzi

Moreno

Ramelli

Han

Weigend

Wan

Lombardi

Genomic study of the response of chicken to highly pathogenic avian influenza virus

BMC Proc. 2011 5 S25

22373290

237.

L.J.

X.Y.

G.Y.

Ning

Z.H.

Yang

Lower antibody response in chickens homozygous for the Mx resistant allele to avian influenza

Asian-Aust. J. Anim. Sci. 2009 22 465 470 238.

Barber

M.R.

Aldridge

J.R.

Jr. Webster

R.G.

Magor

K.E.

Association of RIG-I with innate immunity of ducks to influenza

Proc. Natl. Acad. Sci. U. S. A. 2010 107 5913 5918

10.1073/pnas.1001755107

20308570

239.

Karpala

A.J.

Stewart

McKay

Lowenthal

J.W.

Bean

A.G.

Characterization of chicken Mda5 activity: Regulation of IFN-beta in the absence of RIG-I functionality

J. Immunol. 2011 186 5397 5405

10.4049/jimmunol.1003712

21444763

240.

Liniger

Summerfield

Zimmer

McCullough

K.C.

Ruggli

Chicken cells sense influenza A virus infection through MDA5 and CARDIF signaling involving LGP2

J. Virol. 2012 86 705 717

10.1128/JVI.00742-11

22072756

241.

Adams

S.C.

Xing

Cardona

C.J.

Immune-related gene expression in response to H11N9 low pathogenic avian influenza virus infection in chicken and Pekin duck peripheral blood mononuclear cells

Mol. Immunol. 2009 46 1744 1749

10.1016/j.molimm.2009.01.025

242.

Sarmento

Afonso

C.L.

Estevez

Wasilenko

Pantin-Jackwood

Differential host gene expression in cells infected with highly pathogenic H5N1 avian influenza viruses

Vet. Immunol. Immunopathol. 2008 125 291 302

10.1016/j.vetimm.2008.05.021

18617273

243.

Liang

Q.L.

Luo

Zhou

Dong

J.X.

H.X.

Immune-related gene expression in response to H5N1 avian influenza virus infection in chicken and duck embryonic fibroblasts

Mol. Immunol. 2011 48 924 930

10.1016/j.molimm.2010.12.011

244.

Kuchipudi

S.V.

Dunham

S.P.

Nelli

White

G.A.

Coward

V.J.

Slomka

M.J.

Brown

I.H.

Chang

K.C.

Rapid death of duck cells infected with influenza: A potential mechanism for host resistance to H5N1

Immunol. Cell Biol. 2012 90 116 123

10.1038/icb.2011.17

21423263

245.

Meng

Liu

Sun

Liu

Chicken cyclophilin A is an inhibitory factor to influenza virus replication

Virol. J. 2010 7 372

10.1186/1743-422X-7-372

246.

Hsiang

T.Y.

Zhao

Krug

R.M.

Interferon-induced ISG15 conjugation inhibits influenza A virus gene expression and replication in human cells

J. Virol. 2009 83 5971 5977

10.1128/JVI.01667-08

19357168

247.

Wang

Hinson

E.R.

Cresswell

The interferon-inducible protein viperin inhibits influenza virus release by perturbing lipid rafts

Cell Host Microbe 2007 2 96 105

10.1016/j.chom.2007.06.009

18005724

248.

Watanabe

Fuse

Asano

Tsukahara

Maru

Nagata

Kitazato

Kobayashi

Identification of Hsc70 as an influenza virus matrix protein (M1) binding factor involved in the virus life cycle

FEBS Lett. 2006 580 5785 5790

10.1016/j.febslet.2006.09.040

249.

Honda

Okamoto

Ishihama

Host factor Ebp1: Selective inhibitor of influenza virus transcriptase

Gene. Cell. 2007 12 133 142

10.1111/j.1365-2443.2007.01047.x

250.

Scott

B.B.

Lois

Generation of tissue-specific transgenic birds with lentiviral vectors

Proc. Natl. Acad. Sci. U. S. A. 2005 102 16443 16447

10.1073/pnas.0508437102

251.

Harvey

A.J.

Speksnijder

Baugh

L.R.

Morris

J.A.

Ivarie

Consistent production of transgenic chickens using replication-deficient retroviral vectors and high-throughput screening procedures

Poultry Sci. 2002 81 202 212 252.

Lyall

Irvine

R.M.

Sherman

McKinley

T.J.

Nunez

Purdie

Outtrim

Brown

I.H.

Rolleston-Smith

Sang

Suppression of avian influenza transmission in genetically modified chickens

Science 2011 331 223 226

10.1126/science.1198020

253.

Enserink

Avian influenza. Transgenic chickens could thwart bird flu, curb pandemic risk

Science 2011 331 132 133

10.1126/science.331.6014.132-a

254.

Boon

A.C.

deBeauchamp

Hollmann

Luke

Kotb

Rowe

Finkelstein

Neale

Williams

R.W.

Host genetic variation affects resistance to infection with a highly pathogenic H5N1 influenza A virus in mice

J. Virol. 2009 83 10417 10426

10.1128/JVI.00514-09